Page last updated: 2024-12-08

eicosapentaenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID446284
CHEMBL ID460026
CHEBI ID28364
SCHEMBL ID20469
MeSH IDM0023259

Synonyms (128)

Synonym
eicosapentaenoate
BRD-K47192521-001-02-1
(z,z,z,z,z)-5,8,11,14,17-eicosapentaenoic acid
cis-5,8,11,14,17-eicosapentaenoic acid
cis-5,8,11,14,17-epa
cis-delta(5,8,11,14,17)-eicosapentaenoic acid
all-cis-5,8,11,14,17-icosapentaenoic acid
cis, cis, cis, cis, cis-eicosa-5,8,11,14,17-pentaenoic acid
(5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoic acid
icosapentum
all-cis-5,8,11,14,17-eicosapentaenoic acid
CHEBI:28364 ,
all-cis-icosa-5,8,11,14,17-pentaenoic acid
icosapento
BSPBIO_001328
c20:5n-3,6,9,12,15
LMFA01030759
IDI1_033798
icosapent
ccris 3279
icosapentaenoic acid
timnodonic acid
5,8,11,14,17-eicosapentaenoic acid, (5z,8z,11z,14z,17z)-
5,8,11,14,17-eicosapentaenoic acid, (all-z)- (8ci)
5,8,11,14,17-eicosapentaenoic acid, (all-z)-
5,8,11,14,17-eicosapentaenoic acid, (5z,8z,11z,14z,17z)- (9ci)
5,8,11,14,17-eicosapentaenoic acid (6ci)
(all-cis)-5,8,11,14,17-eicosapentaenoic acid
(all-z)-delta5,8,11,14,17-eicosapentaenoic acid
(all-z)-5,8,11,14,17-eicosapentaenoic acid
C06428
(5z,8z,11z,14z,17z)-eicosapentaenoate
EICOSAPENTAENOIC ACID ,
(5z,8z,11z,14z,17z)-icosapentaenoic acid
5,8,11,14,17-icosapentaenoic acid
(5z,8z,11z,14z,17z)-eicosapentaenoic acid
(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoic acid
10417-94-4
EPA ,
5z,8z,11z,14z,17z-eicosapentaenoic acid
cis-5,8,11,14,17-eicosapentaenoic acid, >=85%, liquid
cis-5,8,11,14,17-eicosapentaenoic acid, >=99%
3GWX
DB00159
NCGC00161344-01
NCGC00161344-02
NCGC00161344-03
NCGC00161344-04
fa 20:5
eicosapentaenoic acid, 5,8,11,14,17-(z,z,z,z,z)-
7F8BF016-B146-4F72-A52E-B9298BA3A9AB ,
HMS1989C10
bdbm50242349
L001256
eicosapentaenoic acid (20:5 n-3)
BML3-B01 ,
icosapent (inn)
D08061
HMS1791C10
HMS1361C10
ropufa 70
CHEMBL460026 ,
incromega e 7010sr
c20:5 (n-3)
eicosapentaenoic acid (c20:5 n3)
epa 45g
eicosa-5z,8z,11z,14z,17z-pentaenoic acid (20:5, n-3)
e0441 ,
all cis-5,8,11,14,17-icosapentaenoic acid
eye-q
icosapento [inn-spanish]
eye q
icosapentum [inn-latin]
epa [drug]
miraxion
unii-aan7qov9ea
aan7qov9ea ,
icosapent [inn]
cas-10417-94-4
dtxsid9041023 ,
tox21_111991
dtxcid7021023
eicosapentaenoic acid [who-dd]
eicosapentaenoic acid (epa) (c20:5 n3)
eicosapentaenoic acid [vandf]
eicosapentaenoic acid [inci]
eicosapentaenoic acid [usp-rs]
eicosapentaenoic acid [mi]
eicosapentaenoic acid [mart.]
S6476
gtpl3362
CCG-208136
CCG-207957
HY-B0660
(5z,8z,11 z,14z,17z)-icosa-5,8,11,14,17-pentaenoic acid
(5z,8z,11z,14z,17z)-eicosa-5,8,11,14,17-pentaenoic acid
z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoic acid
SCHEMBL20469
AC-31072
HMS3402C10
HMS3649D19
J-001125
cis-5,8,11,14,17-eicosapentaenoic acid, analytical standard
cis-5,8,11,14,17-eicosapentaenoic acid, 500 mug/ml in ethanol, certified reference material
5,8,11,14,17-icosapentaenoate
all-cis-icosapentaenoic acid
timnodonate
cis-5,8,11,14,17-eicosapentaenoate
all-cis-icosapentaenoate
5,8,11,14,17-eicosapentaenoate
P16966
AKOS027470327
AS-53730
Q409990
c20h30o2 (cis-5,8,11,14,17-eicosapentaenoic acid)
5z,8z,11z,14z,17z-eicosapentaenoate
sr-01000946647
SR-01000946647-1
NCGC00161344-07
fa(20:5(5z,8z,11z,14z,17z))
EN300-7403855
epa (drug)
icosapentum (inn-latin)
icosapent (epa)
epa-ffa
25377-48-4
reliven
icosapento (inn-spanish)

Research Excerpts

Overview

Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid. EPA is highly effective in reducing cardiovascular events in patients and cardiac fibrosis and hypertrophy in animals when administered before pressure overload.

ExcerptReferenceRelevance
"Eicosapentaenoic Acid (EPA) is an essential ω-3 polyunsaturated fatty acid for human health. "( Progress of metabolic engineering for the production of eicosapentaenoic acid.
Du, F; Geng, SS; Jia, YL; Li, Q; Sun, XM; Wang, LR; Wang, QZ; Xu, YS, 2022
)
2.41
"Eicosapentaenoic acid (EPA) is an omega-3 fatty acid present in fish oil, which is of physiological importance to both humans and fish."( Sustainable production of eicosapentaenoic acid-rich oil from microalgae: Towards an algal biorefinery.
Ghosh, S; Priyadarshini, R; Sachin, S; Sivakumar, R, 2022
)
1.74
"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that is highly effective in reducing cardiovascular events in patients and cardiac fibrosis and hypertrophy in animals when administered before pressure overload by promoting the increase of anti-inflammatory M1 macrophages."( Eicosapentaenoic Acid Ameliorates Cardiac Fibrosis and Tissue Inflammation in Spontaneously Hypertensive Rats.
Gharraee, N; Herrington, D; Medina-Hernandez, D; Meléndez, GC; Pflum, A; Wang, Z; Zhu, X, 2022
)
2.89
"Eicosapentaenoic acid (EPA) is an essential omega-3 polyunsaturated fatty acid that plays a critical role in marine life. "( Labelling of eicosapentaenoic acid with stable isotope
Lagutin, K; Lu, Y; Ryan, J; Tejerina, J; Visnovsky, G; Vyssotski, M, 2023
)
2.72
"The eicosapentaenoic acid (EPA) is an n-3 polyunsaturated fatty acid (PUFA) present in the lipid composition of bovine oocytes. "( Effects of EPA on bovine oocytes matured in vitro with antioxidants: Impact on the lipid content of oocytes and early embryo development.
Anchordoquy, JM; Anchordoquy, JP; Campagna, A; Carranza-Martín, AC; Furnus, CC; Lombardo, DM; Luchetti, C; Nikoloff, N; Pascua, AM; Seoane, A, 2020
)
1.12
"Eicosapentaenoic acid (EPA) is a promising nutrient against sarcopenia and has multifaceted effects on systemic metabolism."( Eicosapentaenoic acid changes muscle transcriptome and intervenes in aging-related fiber type transition in male mice.
Kuribara-Souta, A; Morohashi, KI; Nishimura, M; Tanaka, H; Uehara, M; Yamamoto, M; Yamazaki, H; Yoshikawa, N, 2021
)
2.79
"Eicosapentaenoic acid (EPA) is a long-chain polyunsaturated fatty acid that has been used to treat cachectic cancer. "( Safety of Eicosapentaenoic Acid in Cancer Treatment: Effect on Cancer Cells and Chemotherapy in Vitro.
Aktaş, S; Altun, Z; Ercetin, P; Kantar, M; Olgun, N, 2021
)
2.47
"Eicosapentaenoic acid (EPA) is an omega-3 fatty acid which is an essential nutrient for both humans and animals. "( Photoautotrophic production of eicosapentaenoic acid.
Gu, W; Kavanagh, JM; McClure, DD, 2021
)
2.35
"Eicosapentaenoic acid (EPA) is an unsaturated fatty acid with various bioactivities, including antitumor effects. "( The Mechanism of the Synergistic Anticancer Effect of CDDP and EPA in the TE1 Cell Line.
Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Miyake, S; Ogo, A; Teramoto, F; Ueno, T, 2021
)
2.06
"Eicosapentaenoic acid (EPA) is an omega-3 fatty acid with immunomodulatory and anti-inflammatory effects. "( Eicosapentaenoic acid and 5-HEPE enhance macrophage-mediated Treg induction in mice.
Fukuhara, A; Hayakawa, T; Onodera, T; Otsuki, M; Shimomura, I; Shin, J, 2017
)
3.34
"Eicosapentaenoic acid (EPA) is an ω-3 polyunsaturated fatty acid that plays various beneficial roles in organisms from bacteria to humans. "( Synthesis and Functional Assessment of a Novel Fatty Acid Probe, ω-Ethynyl Eicosapentaenoic Acid Analog, to Analyze the in Vivo Behavior of Eicosapentaenoic Acid.
Kawamoto, J; Kurihara, T; Sato, S; Tokunaga, T; Watanabe, B, 2017
)
2.13
"Eicosapentaenoic acid (EPA) is an omega-3 fatty acid with anti-inflammatory effects. "( Metabolomic Analysis of Diet-Induced Obese Mice Supplemented with Eicosapentaenoic Acid.
Fukuhara, A; Jinno, Y; Kawano, H; Nishitani, S; Otsuki, M; Shimomura, I; Yano, T, 2020
)
2.24
"Eicosapentaenoic acid (EPA) is a key anti-inflammatory/anti-aggregatory long-chain polyunsaturated omega-3 fatty acid. "( The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease.
Nelson, JR; Raskin, S, 2019
)
2.51
"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid (ω-3 PUFA) that protects against photodamage and photocarcinogenesis in mammals. "( EPA attenuates ultraviolet radiation-induced downregulation of aquaporin-3 in human keratinocytes.
Jeon, BK; Kang, MK; Lee, GT; Lee, HS; Lee, KK; Mun, YJ; Woo, WH, 2015
)
1.86
"Eicosapentaenoic acid (EPA) is an antioxidant and n-3 polyunsaturated fatty acid that reduces the production of inflammatory cytokines. "( Oxidative stress-induced apoptosis and matrix loss of chondrocytes is inhibited by eicosapentaenoic acid.
Chinzei, N; Fujishiro, T; Haneda, M; Hashimoto, S; Hayashi, S; Iwasa, K; Kanzaki, N; Kawakita, K; Kihara, S; Kuroda, R; Kurosaka, M; Nishiyama, T; Sakata, S; Ueha, T, 2015
)
2.08
"Eicosapentaenoic acid (EPA) is a triglyceride-lowering agent that reduces circulating levels of the apolipoprotein B (apoB)-containing lipoprotein particles small dense low-density lipoprotein (sdLDL), very-low-density lipoprotein (VLDL), and oxidized low-density lipoprotein (LDL). "( Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.
Jacob, RF; Mason, RP; Sherratt, SC, 2016
)
3.32
"Eicosapentaenoic acid (EPA) is an n-3 fatty acid known to reduce the frequency of nonfatal coronary events; however, the frequency of mortality after myocardial infarction (MI) is not reduced."( Long-Term Administration of Eicosapentaenoic Acid Improves Post-Myocardial Infarction Cardiac Remodeling in Mice by Regulating Macrophage Polarization.
Inoue, O; Kaneko, S; Kurokawa, K; Nomura, A; Okada, H; Ootsuji, H; Takamura, M; Usui, S, 2017
)
1.47
"Eicosapentaenoic acid (EPA) is a omega-3 polyunsaturated fatty acid with anti-inflammatory and anti-cachetic properties that may have potential benefits with regards to skeletal muscle atrophy conditions where inflammation is present. "( The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation.
Allen, J; Magee, P; Pearson, S, 2008
)
2.1
"Eicosapentaenoic acid (EPA) is a member of the family of n-3 polyunsaturated fatty acids (PUFAs) that are clinically used to treat hypertriglyceridemia. "( Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice.
Harada, T; Imada, K; Kajikawa, S; Kawashima, A; Mizuguchi, K, 2009
)
2.14
"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that has anti-inflammatory and anticachectic actions. "( Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors.
Castillero, E; López-Calderón, A; López-Menduiña, M; Martín, AI; Villanúa, MA, 2009
)
3.24
"Eicosapentaenoic acid (EPA) is an agent used clinically to treat hypertriglyceridemia, and has been reported to suppress reactive oxygen species and inflammation."( Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats.
Harada, T; Imada, K; Kajikawa, S; Kawashima, A; Mizuguchi, K, 2010
)
1.43
"Eicosapentaenoic acid (EPA) is a polyunsaturated fatty acid (PUFA) from the omega-3 family that has many beneficial effects in obesity-linked disorders."( Eicosapentaenoic acid up-regulates apelin secretion and gene expression in 3T3-L1 adipocytes.
Bustos, M; Lorente-Cebrián, S; Marti, A; Martinez, JA; Moreno-Aliaga, MJ, 2010
)
2.52
"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid abundant in fish oil that exerts a wide spectrum of documented beneficial health effects in humans. "( The {omega}-3 fatty acid eicosapentaenoic acid elicits cAMP generation in colonic epithelial cells via a "store-operated" mechanism.
Curci, S; Hofer, AM; Lefkimmiatis, K; Moyer, MP; Roy, J, 2010
)
2.11
"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid with beneficial effects in obesity and insulin resistance. "( Eicosapentaenoic acid inhibits tumour necrosis factor-α-induced lipolysis in murine cultured adipocytes.
Bustos, M; Fernández-Galilea, M; Lorente-Cebrián, S; Marti, A; Martinez, JA; Moreno-Aliaga, MJ, 2012
)
3.26
"Eicosapentaenoic acid (EPA) is a polyunsaturated fatty acid present in fish oils used for omega-3 enriched diets. "( Trans fatty acids: chemical synthesis of eicosapentaenoic acid isomers and detection in rats fed a deodorized fish oil diet.
Aoun, M; Chatgilialoglu, C; Coudray, C; Feillet-Coudray, C; Ferreri, C; Fouret, G; Grabovskiy, SA; Kabal'nova, N; Melchiorre, M, 2012
)
2.09
"Eicosapentaenoic acid (EPA) is a polyunsaturated n-3 fatty acid and is essential to the health of mammals. "( Anti-genotoxic role of eicosapentaenoic acid against imazalil-induced DNA damage in vitro.
Aydin, E; Turkez, H, 2013
)
2.14
"Eicosapentaenoic acid is a fish oil fatty acid that has been shown to decrease blood pressure (BP) in humans. "( Eicosapentaenoic acid inhibits Ca2+ mobilization and PKC activity in vascular smooth muscle cells.
Gabrielian, A; Hori, MT; Nyby, MD; Ormsby, B; Tuck, ML, 2003
)
3.2
"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that plays an important role in the regulation of biological functions and prevention and treatment of a number of human diseases such as heart and inflammatory diseases. "( Heterotrophic production of eicosapentaenoic acid by microalgae.
Chen, F; Wen, ZY, 2003
)
2.06
"Eicosapentaenoic acid (EPA) is an omega-3 fatty acid which is known to induce cell cycle arrest and apoptosis in pancreatic tumour cells."( Eicosapentaenoic acid perturbs signalling via the NFkappaB transcriptional pathway in pancreatic tumour cells.
Fearon, KC; Maingay, JP; Powell, JJ; Ross, JA; Sangster, K, 2003
)
2.48
"Eicosapentaenoic acid (EPA) is a dietary polyunsaturated fatty acid (PUFA) that is found abundantly in fish oils and induces apoptosis in human promyelocytic leukemia HL-60 cells. "( Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein.
Chiu, LC; Ooi, VE; Tong, KF, 2004
)
2.04
"Eicosapentaenoic acid is an omega-3 fatty acid, a group of fatty acids characterized by a double bond that sits three carbons down from the n terminal of the molecule. "( Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome?
Jatoi, A, 2005
)
2.02
"Eicosapentaenoic acid (EPA) is a dietary n-3 polyunsaturated fatty acid that improves insulin sensitivity in several models of obesity and diabetes, which has been suggested to be related to adiponectin induction."( Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes.
Lorente-Cebrián, S; Marti, A; Martínez, JA; Moreno-Aliaga, MJ; Pérez-Matute, P, 2006
)
1.45
"Eicosapentaenoic acid (EPA) is a long chain polyunsaturated fatty acid found naturally in some fish which has been used to decrease weight loss, promote weight gain and increase survival times in patients affected with cancer cachexia."( Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia.
Baughan, C; Dean, T; Dewey, A; Higgins, B; Johnson, I, 2007
)
2.5
"Eicosapentaenoic acid (EPA) is an omega-3 (omega-3) polyunsaturated fatty acid (PUFA), which has anti-inflammatory and anti-cancer properties. "( Eicosapentaenoic acid inhibits TNF-alpha-induced matrix metalloproteinase-9 expression in human keratinocytes, HaCaT cells.
Chung, JH; Eun, HC; Kim, HH; Lee, Y, 2008
)
3.23
"Eicosapentaenoic acid is a better inhibitor of platelet activation induced by various agonists in washed platelets than dihomogammalinolenic acid."( Dihomogammalinolenic acid, but not eicosapentaenoic acid, activates washed human platelets.
Lapetina, EG; Siegel, FL; Siess, W, 1984
)
1.27
"Eicosapentaenoic acid (EPA) is a poor substrate for the fatty acid cyclo-oxygenase but is a good substrate for lipoxygenase enzymes which catalyse the biosynthesis of hydroperoxy-acids, hydroxy-acids and leukotrienes. "( Effect of orally administered eicosapentaenoic acid (EPA) on the formation of leukotriene B4 and leukotriene B5 by rat leukocytes.
Moncada, S; Salmon, JA; Terano, T, 1984
)
2
"Eicosapentaenoic acid, which is a major fatty acid in fish oil, previously has been shown to competitively inhibit the cyclooxygenase-catalyzed metabolism of arachidonic acid in platelets. "( The effect of eicosapentaenoic acid on leukotriene B production by human neutrophils.
Prescott, SM, 1984
)
2.07
"Eicosapentaenoic acid (EPA) is an unsaturated fatty acid contained in fish oils. "( Eicosapentaenoic acid modulates arachidonic acid metabolism in rat alveolar macrophages.
Kitamura, S; Kobayashi, J; Yokoyama, S, 1995
)
3.18
"Eicosapentaenoic acid (EPA) is a polyunsaturated fatty acid (20:5omega3) found primarily in aquatic organisms. "( Eicosapentaenoic acid modulates cyclin expression and arrests cell cycle progression in human leukemic K-562 cells.
Chiu, LC; Ooi, VE; Wan, JM, 2001
)
3.2
"Eicosapentaenoic acid (EPA) is a prominent polyunsaturated fatty acid in fish oil which inhibits blood platelet aggregation and thromboxane A2 formation but not prostacyclin-like material generation from vascular endothelium. "( Arachidonic acid strongly stimulates prostaglandin I3 (PGI3) production from eicosapentaenoic acid in human endothelial cells.
Bordet, JC; Guichardant, M; Lagarde, M, 1986
)
1.94

Effects

Eicosapentaenoic acid (EPA) has been reported to have a potent anti-aggregatory activity and to be efficiently metabolized by 12-lipoxygenase. EPA has been shown to modulate NFĸB, but evidence for its benefit around the time of surgery is limited.

ExcerptReferenceRelevance
"Eicosapentaenoic acid (20:5, n-3) has a triglyceride- and cholesterol-reducing effect by inhibition of the VLDL-synthesis (apolipoprotein B, triglycerides) in the liver, inhibition of lipogenic liver enzymes, accelerated elimination of VLDL from the circulation, increased excretion of steroids and bile acids into the stools and amelioration of the fat tolerance."( [Decreasing atherogenic risks by an eicosapentaenoic acid-rich diet].
Beitz, J; Herrmann, W, 1987
)
1.27
"Eicosapentaenoic acid (EPA) has been reported to possess an antihypertensive effect, and our previous study suggested that EPA-enriched phospholipid (EPA-PL) had more significant bioactivities compared with traditional EPA."( EPA-Enriched Phospholipids Alleviate Renal Interstitial Fibrosis in Spontaneously Hypertensive Rats by Regulating TGF-β Signaling Pathways.
Chen, LP; Shi, HH; Wang, CC; Wang, YM; Xue, CH; Yang, JY; Zhang, LY; Zhang, TT, 2022
)
1.44
"Eicosapentaenoic acid (EPA) has been recognized as a promising nutrient to improve therapeutic efficacy for cancer patients. "( Synthesis of eicosapentaenoic acid-enriched medium- and long-chain triglyceride by lipase-catalyzed transesterification: a novel strategy for clinical nutrition intervention.
Chang, M; Jin, Q; Liu, R; Wang, X; Wang, Y; Wei, W, 2023
)
2.72
"Eicosapentaenoic acid (EPA) has shown beneficial effects on coronary plaque stabilization. "( Association between Eicosapentaenoic Acid to Arachidonic Acid Ratio and Characteristics of Plaque Rupture.
Arai, K; Arai, T; Koba, S; Kondo, S; Masaki, R; Matsukawa, N; Mizukami, T; Mori, H; Nomura, K; Ogura, K; Oishi, Y; Sakai, K; Sakai, R; Sato, S; Sekimoto, T; Shinke, T; Suzuki, H; Tanaka, H; Tsujita, H; Tsukamoto, S; Yamamoto, MH; Yokota, Y, 2023
)
2.68
"Eicosapentaenoic acid (EPA) has been reported to play an anti-inflammatory and antioxidative stress role in a series of human diseases, including major depressive disorder. "( miR-29a-3p promotes the regulatory role of eicosapentaenoic acid in the NLRP3 inflammasome and autophagy in microglial cells.
Huang, LY; Jin, Q; Pan, JP; Tang, DF; Wang, W; Wu, QZ; Xie, JL; Yang, MF, 2023
)
2.62
"Eicosapentaenoic acid (EPA) has been shown to suppress inflammation in macrophages and adipocytes."( Eicosapentaenoic acid supplementation modulates the osteoblast/osteoclast balance in inflammatory environments and protects against estrogen deficiency-induced bone loss in mice.
Chen, H; Hang, K; Li, L; Pan, Z; Shi, J; Wang, K; Wang, Z; Wu, J; Wu, X; Xue, D; Zhang, W; Zhou, C, 2023
)
3.07
"Eicosapentaenoic acid (EPA) has been shown to modulate NFĸB, but evidence for its benefit around the time of surgery is limited."( A double-blind randomized controlled trial of the effects of eicosapentaenoic acid supplementation on muscle inflammation and physical function in patients undergoing colorectal cancer resection.
Doleman, B; Hossain, T; Lund, JN; Phillips, BE; Williams, JP, 2020
)
1.52
"Eicosapentaenoic acid (EPA) has garnered attention after the success of the REDUCE-IT trial, which contradicted previous conclusions on EPA for cardiovascular disease risk. "( Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner.
Al-Shaer, AE; Armstrong, M; Bazinet, RP; Carroll, I; Clària, J; Davis, T; Guesdon, W; Halade, GV; Neufer, PD; Pal, A; Quinn, K; Reisdorph, N; Shaikh, SR; Spangenburg, EE; Torres, MJ, 2020
)
2.3
"Eicosapentaenoic acid (EPA) has been reported to reduce cardiovascular risk in patients with hypertriglyceridemia. "( Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
Fukumoto, K; Iguchi, T; Namikawa, H; Norioka, N; Shuto, T; Takemoto, Y; Tochino, Y; Yoshikawa, J; Yoshiyama, M, 2020
)
2.2
"Eicosapentaenoic acid (EPA) has been reported to improve clinical outcome of high-risk atherosclerotic patients. "( Eicosapentaenoic acid levels predict prognosis of peripheral artery disease caused by aortoiliac artery lesions.
Abe, F; Hikita, H; Hishikari, K; Iiya, M; Ito, N; Kanno, Y; Murai, T; Sasano, T; Takahashi, A; Yonetsu, T, 2021
)
3.51
"Eicosapentaenoic acid (EPA) has been shown to suppress immune cell responses, such as cytokine production and downstream PG production in vitro. "( Eicosapentaenoic acid suppression of systemic inflammatory responses and inverse up-regulation of 15-deoxyΔ(12,14) prostaglandin J2 production.
Davidson, J; Higgs, W; Rotondo, D, 2013
)
3.28
"Eicosapentaenoic acid (EPA) has beneficial effects in many inflammatory disorders. "( Eicosapentaenoic acid is converted via ω-3 epoxygenation to the anti-inflammatory metabolite 12-hydroxy-17,18-epoxyeicosatetraenoic acid.
Arai, H; Arita, M; Goto, T; Inoue, M; Isobe, Y; Iwamoto, R; Kubota, T; Urabe, D; Yoshioka, T, 2014
)
3.29
"Eicosapentaenoic acid (EPA) has been reported to augment endothelial function and improve clinical outcomes in patients with coronary artery disease (CAD). "( Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease.
Ando, T; Inoue, Y; Isshiki, A; Ito, H; Kamiyama, T; Kirimura, M; Maruyama, Y; Nishioka, T; Sasaki, O; Toyama, K; Yoshimoto, N, 2014
)
3.29
"Eicosapentaenoic acid (EPA) has antiarrhythmic effects. "( Low serum eicosapentaenoic acid level is a risk for ventricular arrhythmia in patients with acute myocardial infarction: a possible link to J-waves.
Abe, N; Echizen, T; Endo, T; Higuma, T; Ishida, Y; Kushibiki, M; Murakami, K; Okumura, K; Osanai, T; Saitoh, S; Suzuki, A; Tateyama, S; Tomita, H; Yamada, M; Yokota, T; Yokoyama, H, 2014
)
2.25
"Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects."( Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.
Arrieta, O; De la Torre-Vallejo, M; Guevara, P; Juárez-Hernández, E; Mohar, A; Nuñez-Valencia, C; Sánchez-Lara, K; Turcott, JG; Villanueva, G, 2014
)
1.37
"Eicosapentaenoic acid (EPA) has been widely accepted to have antiatherosclerotic effects. "( Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation.
Hosogoe, N; Ishikawa, S; Isshiki, T; Takada, K; Yokoyama, N, 2014
)
2.23
"Eicosapentaenoic acid (EPA) has been identified as a promising nutrient with the wide clinical benefits."( Eicosapentaenoic acid in cancer improves body composition and modulates metabolism.
Almeida, A; Pappalardo, G; Ravasco, P, 2015
)
2.58
"Eicosapentaenoic acid (EPA) has been shown to attenuate muscle atrophy in cancer, starvation and hyperthermia by downregulating the increased expression of the ubiquitin-proteasome proteolytic pathway leading to a reduction in protein degradation. "( Downregulation of muscle protein degradation in sepsis by eicosapentaenoic acid (EPA).
Khal, J; Tisdale, MJ, 2008
)
2.03
"Eicosapentaenoic acid (EPA) has been known as a reagent for improving lipid metabolism and inflammation. "( Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.
Anezaki, Y; Dohmen, T; Goto, T; Horie, Y; Ishii, H; Kataoka, E; Kinoshita, N; Ohnishi, H; Ohshima, S; Sasaki, J; Sasaki, T; Sato, W; Suzuki, A; Watanabe, S, 2009
)
3.24
"Eicosapentaenoic acid has been tested in bladder cancer as a synergistic cytotoxic agent in the form of meglumine-eicosapentaenoic acid, although its mechanism of action is poorly understood in this cancer. "( Mechanisms of action of eicosapentaenoic acid in bladder cancer cells in vitro: alterations in mitochondrial metabolism, reactive oxygen species generation and apoptosis induction.
Colquhoun, A, 2009
)
2.1
"Eicosapentaenoic acid (EPA) has been shown to have beneficial effects on cardiovascular diseases, although the precise mechanism is unknown. "( Orally administered eicosapentaenoic acid induces rapid regression of atherosclerosis via modulating the phenotype of dendritic cells in LDL receptor-deficient mice.
Hirata, K; Ishida, T; Kasahara, K; Kita, T; Nakajima, K; Rikitake, Y; Sasaki, N; Shinohara, M; Takeda, M; Yamashita, T; Yokoyama, M, 2011
)
2.14
"Eicosapentaenoic acid (EPA) has been shown to have anti-inflammatory and tumor growth inhibitory effects clinically and experimentally; evidence also supports the role of EPA in attenuating cancer-associated weight loss, but the mechanisms of these effects remain to be defined. "( Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy.
Babcock, TA; Espat, NJ; Helton, WS; Jho, DH; Tevar, R,
)
3.02
"Eicosapentaenoic acid (EPA) has been shown to attenuate the enhanced protein degradation, but to have no effect on protein synthesis."( Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice.
Greenberg, NA; Smith, HJ; Tisdale, MJ, 2004
)
1.45
"Eicosapentaenoic acid (EPA) has been demonstrated to induce apoptosis and cell cycle arrest in various cancer cell lines in vitro. "( Eicosapentaenoic acid induces Fas-mediated apoptosis through a p53-dependent pathway in hepatoma cells.
Chen, GG; Chi, TY; Lai, PB,
)
3.02
"Eicosapentaenoic acid (EPA) has been shown to exert anti-inflammatory actions. "( Effects of eicosapentaenoic acid supplementation in the treatment of chronic hepatitis C patients.
Kakibuchi, N; Kawakami, T; Kita, K; Murakami, Y; Okita, M; Takaguchi, K; Tomioka, K, 2005
)
2.16
"Eicosapentaenoic acid (EPA) has been proposed to have specific anticachectic effects. "( Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.
Ahmedzai, SH; Barber, MD; Fearon, KC; Moses, AG; Murray, GD; Taylor, GS; Tisdale, MJ, 2006
)
2.02
"Eicosapentaenoic acid (EPA) has been reported to have beneficial effects on the progression of various renal diseases including diabetic nephropathy; however, the precise mechanisms are not completely understood. "( Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress.
Gohda, T; Gu, L; Hagiwara, S; Horikoshi, S; Kaneko, S; Matsumoto, M; Nakamura, S; Qian, J; Tanimoto, M; Tomino, Y; Zhang, M, 2006
)
2.17
"Eicosapentaenoic acid (EPA) has been reported to improve postischemic cerebral blood flow (CBF). "( Sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate (U-63557A) potentiates protective effect of intravenous eicosapentaenoic acid on impaired CBF in ischemic gerbils.
Black, KL; Hoff, JT; Hsu, S; Radin, NS, 1984
)
1.92
"Eicosapentaenoic acid (EPA) has been reported to be anti-aggregatory in humans, but it is difficult to confirm that anti-aggregatory effect in rat. "( A proposed method for exploring anti-aggregatory effects of eicosapentaenoic acid in the rat.
Komeshima, N; Morita, I; Murota, S; Orimo, H; Takahashi, R, 1984
)
1.95
"Eicosapentaenoic acid EPA has been shown to be of major importance in the prevention and treatment of a range of human diseases and disorders. "( Eicosapentaenoic acid (EPA) production from microorganisms: a review.
Bajpai, P; Bajpai, PK, 1993
)
3.17
"Eicosapentaenoic acid (EPA) has been shown to have an inhibitory effect on the growth of several pancreatic cancer cell lines in vitro. "( Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro.
Anderson, JD; Carter, DC; Fearon, KC; Lai, PB; Ross, JA, 1996
)
1.96
"Eicosapentaenoic acid (EPA) has anticancer effects both in vitro and in animal models."( Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia.
Barber, MD; Fearon, KC, 2001
)
1.29
"Eicosapentaenoic acid (EPA) has been reported to have a potent anti-aggregatory activity and to be efficiently metabolized by 12-lipoxygenase, not by cyclooxygenase in platelets. "( Comparison of the in vitro effect of eicosapentaenoic acid (EPA)-derived lipoxygenase metabolites on human platelet function with those of arachidonic acid.
Hirai, A; Kitagawa, H; Takenaga, M; Tamura, Y; Terano, T; Yoshida, S, 1986
)
1.99
"Eicosapentaenoic acid (20:5, n-3) has a triglyceride- and cholesterol-reducing effect by inhibition of the VLDL-synthesis (apolipoprotein B, triglycerides) in the liver, inhibition of lipogenic liver enzymes, accelerated elimination of VLDL from the circulation, increased excretion of steroids and bile acids into the stools and amelioration of the fat tolerance."( [Decreasing atherogenic risks by an eicosapentaenoic acid-rich diet].
Beitz, J; Herrmann, W, 1987
)
1.27

Actions

Eicosapentaenoic acid (EPA) can inhibit photocarcinogenesis, but due to its polyunsaturated nature it is susceptible to oxidative damage by ROS. EPA does not activate platelets and is poorly metabolized by platelet cyclooxygenase and lipoxygen enzyme.

ExcerptReferenceRelevance
"Eicosapentaenoic acid (EPA) may suppress this response."( Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid.
Ferguson, ML; Gaff, RL; Hustead, DS; Nelson, JL; Voss, AC; Weed, HG, 2011
)
1.29
"Eicosapentaenoic acid does not activate platelets and is poorly metabolized by platelet cyclooxygenase and lipoxygenase."( Dihomogammalinolenic acid, but not eicosapentaenoic acid, activates washed human platelets.
Lapetina, EG; Siegel, FL; Siess, W, 1984
)
1.27
"Eicosapentaenoic acid (EPA) can inhibit photocarcinogenesis, but due to its polyunsaturated nature it is susceptible to oxidative damage by ROS."( Topically applied eicosapentaenoic acid protects against local immunosuppression induced by UVB irradiation, cis-urocanic acid and thymidine dinucleotides.
Beijersbergen van Henegouwen, GM; Moison, RM; Steenvoorden, DP, 2001
)
1.37
"Eicosapentaenoic acid was found to inhibit basal and stimulated prostanoid production whereas docosahexaenoic acid inhibited basal but strongly increased stimulated prostanoid production."( Profile of eicosanoids produced by human saphenous vein endothelial cells and the effect of dietary fatty acids.
Nicolaou, A; Parkin, SM; Urquhart, P, 2001
)
1.03
"Eicosapentaenoic acid caused lower cholesterol esterification than oleic acid in the concentration range 0.2-1.0 mM fatty acid and reduced the stimulatory effect of oleic acid on cholesterol ester formation."( Eicosapentaenoic acid inhibits cholesterol esterification in cultured parenchymal cells and isolated microsomes from rat liver.
Drevon, CA; Nossen, JO; Osmundsen, H; Rustan, AC, 1988
)
2.44

Treatment

Eicosapentaenoic acid pretreatment enriched itself in the membrane of intestinal cells. Treatment increased TNFα secretion in subcutaneous stromovascular cells at 25, 50, and 100 μM (P = 0.002, P -1.001, and P’-2.015)

ExcerptReferenceRelevance
"Eicosapentaenoic acid treatment increased TNFα secretion in subcutaneous stromovascular cells at 25, 50, and 100 μM (P = 0.002, P = 0.001, and P = 0.015, respectively) and in visceral stromovascular cells at 50 μM (P < 0.001)."( Adipokines secretion in feline primary adipose tissue culture in response to dietary fatty acids.
Bolin, SR; Mazaki-Tovi, M; Schenck, PA, 2019
)
1.24
"Eicosapentaenoic acid pretreatment enriched itself in the membrane of intestinal cells."( EICOSAPENTAENOIC ACID ENHANCES HEATSTROKE-IMPAIRED INTESTINAL EPITHELIAL BARRIER FUNCTION IN RATS.
Geng, Y; Liu, Z; Lu, J; Qiu, X; Su, L; Tang, L; Xiao, G; Yuan, F; Zhang, Y, 2015
)
2.58
"Eicosapentaenoic acid treatment (24 h), alone and in the presence of TNF-α, also decreased adipose triglyceride lipase (ATGL) protein content in cultured adipocytes."( Eicosapentaenoic acid inhibits tumour necrosis factor-α-induced lipolysis in murine cultured adipocytes.
Bustos, M; Fernández-Galilea, M; Lorente-Cebrián, S; Marti, A; Martinez, JA; Moreno-Aliaga, MJ, 2012
)
2.54
"Eicosapentaenoic acid treated cells produced less prostaglandin E2 but had increased inducible nitric oxide synthase expression, nitric oxide production, collagen formation, and recoverage area during in-vitro wound healing than cells treated with arachidonic acid. "( Inducible nitric oxide synthase links NF-kappaB to PGE2 in polyunsaturated fatty acid altered fibroblast in-vitro wound healing.
Jia, Y; Turek, JJ, 2005
)
1.77
"In eicosapentaenoic acid treated gerbils blood flow decreased initially but after 2 h of reperfusion blood flow was significantly higher than in control gerbils."( Effect of intravenous eicosapentaenoic acid on cerebral blood flow, edema and brain prostaglandins in ischemic gerbils.
Black, KL; Hoff, JT; Hsu, S; Radin, NS, 1984
)
1.1
"Eicosapentaenoic acid treatment was associated with a reduction, and linoleic acid treatment with an increase in the relative proportions of arachidonic acid found in cell phospholipids."( Inhibition of vasopressin-induced formation of diradylglycerols in vascular smooth muscle cells by incorporation of eicosapentaenoic acid in membrane phospholipids.
Falardeau, P; Hui, R; Robillard, M, 1992
)
1.21
"The eicosapentaenoic acid pretreatment also potentiated cell migration activity in response to several other chemotactic factors such as basic fibroblast growth factor, tumor necrosis factor-alpha and leukotriene C4."( Enhancement of migration in bovine endothelial cells by eicosapentaenoic acid pretreatment.
Ito, H; Kanayasu, T; Morita, I; Murota, S; Nakao-Hayashi, J, 1991
)
1.01
"Eicosapentaenoic acid treatment (40 microM) inhibited incorporation of radioactive linoleic acid and actively reduced radioactivity of desaturation-elongation metabolites in phospholipids, predominantly in the phosphatidylethanolamine fraction."( Effects of eicosapentaenoic acid and arachidonic acid on incorporation and metabolism of radioactive linoleic acid in cultured human fibroblasts.
Begin, ME; Ells, G; Horrobin, DF; Takahashi, R, 1991
)
1.39
"The treatment with eicosapentaenoic acid significantly increased the relaxation of the bioassay ring observed upon stimulation of the endothelial cells with adenosine diphosphate (3 x 10(-8) M to 3 x 10(-4) M) and, to a lesser extent with bradykinin (10(-8) to 3 x 10(-8) M), while the relaxing activity evoked by the calcium ionophore A23187 (3 x 10(-7) M) was not affected."( Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s).
Boulanger, C; Hendrickson, H; Schini, VB; Vanhoutte, PM, 1990
)
0.85

Toxicity

ExcerptReferenceRelevance
" The results indicate an up to now unknown side effect of the propranolol therapy which is to be seen in the connection with other unfavourable effects in the lipid metabolism."( [Modification of vasoprotective omega-3-fatty acids--a previously unknown side effect of propranolol therapy?].
Mädebach, H; Reuter, W; Zander, B, 1988
)
0.27
"Methanol extracts of the hepatopancreas of mussels (Mytilus edulis) harvested at two locations (Ship Harbour and Wine Harbour) in eastern Nova Scotia, Canada, were found to be toxic to mice after intraperitoneal injection."( An incident of elevated levels of unsaturated free fatty acids in mussels from Nova Scotia and their toxic effect in mice after intraperitoneal injection.
Chadha, RK; Lawrence, JF; Ratnayake, WM; Truelove, JF, 1994
)
0.29
" Undecanal and EPA showed a limited toxic effect in naupliar mortality trials."( The use of a brine shrimp (Artemia salina) bioassay to assess the toxicity of diatom extracts and short chain aldehydes.
Bentley, MG; Caldwell, GS; Olive, PJ, 2003
)
0.32
" Taken as whole, the toxic effect of the FA on insulin-producing RINm5F cells varied irrespective of the chain length and the degree of unsaturation."( Fatty acid-induced toxicity and neutral lipid accumulation in insulin-producing RINm5F cells.
Azevedo-Martins, AK; Curi, R; Lenzen, S; Lima, CL; Monteiro, AP, 2006
)
0.33
"Our findings indicate that the administration of Lipoplus in the postoperative period after major abdominal surgery is safe and results in a significantly shorter length of hospital stay."( Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial.
Czarnetzki, HD; Jauch, KW; Kemen, M; Morlion, BJ; Thul, P; Wichmann, MW, 2007
)
0.34
" Adverse event reporting was similar for the two groups."( Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
Ascott-Evans, B; Chiliza, B; Emsley, R; Koen, L; Niehaus, DJ; Oosthuizen, PP; Smit, RM; van Rensburg, SJ, 2008
)
0.63
" Current pharmacologic treatment options are associated with the potential for significant adverse events, which often outweigh the benefits of achieving sinus rhythm."( Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
Ellenbogen, KA; Kowey, PR; Naccarelli, GV; Pratt, CM; Reiffel, JA, 2009
)
0.35
" Exposure to EPA oil for 90 days produced no effects at 98 mg EPA/kg/day and no adverse effects at doses up to 976 mg EPA/kg/day."( Safety assessment of EPA-rich oil produced from yeast: Results of a 90-day subchronic toxicity study.
Belcher, LA; Frame, SR; Gillies, PJ; MacKenzie, SA; Mukerji, P; Sykes, GP, 2010
)
0.36
" Our findings suggest that this toxic model is not reflective or predictive of findings in genetic mouse models, and may not be useful as a preclinical screen for HD therapeutics."( Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Leavitt, BR; Sivananthan, SN, 2011
)
0.69
" Statins induced various toxic changes in RD cells, and EPA attenuated all of these changes."( Eicosapentaenoic acid attenuates statin-induced ER stress and toxicity in myoblast.
Imada, K; Kawano, H; Naba, H; Notsu, T; Ohta, M, 2012
)
1.82
" irregulare can be considered a safe source of biomass and EPA-containing oil for use as ingredients in dietary supplements, food, feed and pharmaceuticals."( The safety assessment of Pythium irregulare as a producer of biomass and eicosapentaenoic acid for use in dietary supplements and food ingredients.
Roe, CL; Wen, Z; Wu, L, 2013
)
0.62
"TAK-085 was safe and well tolerated for up to 52 weeks of treatment in Japanese patients with hypertriglyceridemia undergoing lifestyle modification."( Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
Kudou, K; Ootake, J; Saito, Y; Tatsuno, I,
)
0.13
" The no observed adverse effect level for Almega PL was 2000 mg/kg/d."( Safety assessment of EPA-rich polar lipid oil produced from the microalgae Nannochloropsis oculata.
Ballou, CM; Gad, SC; Kagan, ML; Sullivan, DW,
)
0.13
" The incidence of adverse events was not significantly different between the 2 groups."( Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Ahn, CW; Byun, DW; Han, KA; Han, KH; Hong, SJ; Hong, YJ; Hur, SH; Jeon, HK; Kim, CH; Kim, DB; Kim, HS; Kim, IJ; Kim, S; Kim, SH; Kim, SY; Lee, H; Lee, KJ; Lee, SH; Lim, HS; Lim, SW; Min, K; Park, IB; Sung, J; Won, K; Yu, J, 2018
)
0.48
"Among the 21 included RCTs (total 24,460 participants; 12,750 from RxOME3FA treatment cohort and 11,710 from control cohort), there was no definite evidence of any RxOME3FA-emerging serious adverse event."( Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials.
Chang, CH; Chang, JP; Chen, NY; Kuo, FY; Lin, J; Lin, PC; Lin, PY; Su, KP; Tseng, PT; Wu, MC, 2018
)
0.48
"RxOME3FAs are generally safe and well tolerated but not free of adverse effects."( Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials.
Chang, CH; Chang, JP; Chen, NY; Kuo, FY; Lin, J; Lin, PC; Lin, PY; Su, KP; Tseng, PT; Wu, MC, 2018
)
0.48
" No signs of toxicity were evident and no adverse effects were noted in clinical observations, clinical pathology, or histopathology."( Safety assessment of EPA+DHA canola oil by fatty acid profile comparison to various edible oils and fat-containing foods and a 28-day repeated dose toxicity study in rats.
Andre, C; Buesen, R; Lipscomb, EA; Marxfeld, H; Riffle, B; Sottosanto, JB; Strauss, V; van Ravenzwaay, B; Wandelt, C, 2019
)
0.51
" Some of the earlier studies have reported several, non-serious adverse events, mostly related to gastrointestinal tract, but systematic sufficiently powered study on safety is lacking."( Prospective, randomized, double-blinded, placebo-controlled study on safety and tolerability of the krill powder product in overweight subjects with moderately elevated blood pressure.
Bruheim, I; Marvola, T; Sarkkinen, ES; Savolainen, MJ; Taurio, J, 2018
)
0.48
" The reported adverse events in the groups were compared as primary endpoint and haematological safety parameters and changes in systolic and diastolic pressure and blood total and lipoprotein lipids were measured as secondary end points."( Prospective, randomized, double-blinded, placebo-controlled study on safety and tolerability of the krill powder product in overweight subjects with moderately elevated blood pressure.
Bruheim, I; Marvola, T; Sarkkinen, ES; Savolainen, MJ; Taurio, J, 2018
)
0.48
"There were in total 80 reported adverse events during the follow-up; 50 in placebo and 30 in krill powder group."( Prospective, randomized, double-blinded, placebo-controlled study on safety and tolerability of the krill powder product in overweight subjects with moderately elevated blood pressure.
Bruheim, I; Marvola, T; Sarkkinen, ES; Savolainen, MJ; Taurio, J, 2018
)
0.48
"The results seem to indicate that using krill powder as a source for EPA and DHA is safe in therapeutic dose and the risk of adverse events, let alone serious ones, is low."( Prospective, randomized, double-blinded, placebo-controlled study on safety and tolerability of the krill powder product in overweight subjects with moderately elevated blood pressure.
Bruheim, I; Marvola, T; Sarkkinen, ES; Savolainen, MJ; Taurio, J, 2018
)
0.48
" Moreover, DHA and EPA administrations were related to various adverse consequences, including weight loss and lesions in the respiratory and cardiovascular systems."( Embryo-toxicity of docosahexaenoic and eicosapentaenoic acids: In vivo and in silico investigations using the chick embryo model.
Ansari, M; Dabiri, S; Karamad, E; Khosravi, A; Mortazaeizdeh, A; Mosallanejad, SS; Salari, Z; Salarkia, E; Sharifi, F; Tavakkoli, H, 2021
)
0.89
"4%-7% proliferation of fibroblasts, but did not protect them from the toxic effect of cisplatin."( Safety of Eicosapentaenoic Acid in Cancer Treatment: Effect on Cancer Cells and Chemotherapy in Vitro.
Aktaş, S; Altun, Z; Ercetin, P; Kantar, M; Olgun, N, 2021
)
1.02
" However, prior medications with triglyceride-lowering effects have not reduced adverse clinical outcomes in the statin era."( Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
Bhatt, DL; Mason, RP; Pareek, M, 2022
)
0.72
" MND-2119 was safe and well tolerated."( Efficacy and safety of self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (MND-2119) versus highly purified eicosapentaenoic acid ethyl ester in patients with hypertriglyceridemia: Results from a 12-week randomized, double-b
Hayashi, K; Mori, T; Murasaki, K; Yokoyama, Y,
)
0.36
"The incidence of adverse events in MND-2119 2 g/day and MND-2119 4 g/day was 70."( Long-term safety and efficacy of MND-2119 (self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester) in patients with hypertriglyceridemia: Results from a multicenter, 52-week, open-label study.
Mori, T; Murasaki, K; Yokoyama, Y,
)
0.35
"There is no comprehensive review of the evidence to support omega-3 polyunsaturated fatty acids (PUFAs) as a relatively safe and tolerable intervention."( Safety of Supplementation of Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Chang, CH; Chang, JP; Chou, PH; Su, H; Su, KP; Tseng, PT; Zeng, BS, 2023
)
0.91

Pharmacokinetics

Study assessed the pharmacokinetic profile of eicosapentaenoic acid (EPA), as the free fatty acid (FFA), in an enteric-coated preparation, in 10 ulcerative colitis and 10 Crohn's disease patients.

ExcerptReferenceRelevance
" Pharmacokinetic analyses indicated that fasting plasma GLA and EPA levels plateaued within 7 days' daily consumption at all levels of intake, whereas the time to maximum plasma concentration (Tmax) was shorter for GLA than for EPA."( Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects.
Chilton, FH; Edens, MB; Koumenis, IL; Surette, ME; Tramposch, KM, 2003
)
0.32
"To assess the comparative pharmacokinetic profile and bioavailability of docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) after multiple-dose administration of a new oral formulation (test formulation) and a commercially available reference formulation in healthy subjects."( Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers.
Di Stefano, AF; Doig, MV; Perucca, E; Rusca, A; Scarsi, C, 2009
)
0.79
" When the assessment was performed using baseline values as covariate, test-to-reference ratios for area under the curve (AUCss(0-8)) and for peak concentration (Css(max)) after the last administration on day 28 met bioequivalence criteria (i."( Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers.
Di Stefano, AF; Doig, MV; Perucca, E; Rusca, A; Scarsi, C, 2009
)
0.57
" On the other hand, pharmacokinetic analyses revealed that joint EPA administration had no effect on serum VPA concentrations."( Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: dynamic synergy and therapeutic utility.
Abdel-Aziz, A; Abdel-Dayem, MA; El-Azab, MF; El-Mowafy, AM; Said, SA,
)
1.57
" The objective of this study was to evaluate the effect of IPE on the pharmacokinetic and anticoagulation pharmacodynamics of warfarin, a substrate of cytochrome P450 2C9-mediated metabolism."( Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.
Braeckman, RA; Soni, PN; Stirtan, WG, 2014
)
0.4
" Primary pharmacokinetic end points were area under the concentration-versus-time curve from zero to infinity (AUC(0-∞)) and maximum plasma concentration (C(max)) for R- and S-warfarin; pharmacodynamic end points were area under the international normalized ratio (INR) effect-time curve after the warfarin dose (AUC(INR)) and maximum INR (INR(max))."( Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.
Braeckman, RA; Soni, PN; Stirtan, WG, 2014
)
0.4
" In this study we analyzed the pharmacokinetic profile of eicosapentaenoic acid (EPA), as the free fatty acid (FFA), in an enteric-coated preparation, in 10 ulcerative colitis (UC) and 10 Crohn's disease (CD) patients and 15 healthy volunteers (HV)."( The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid.
Belluzzi, A; Cardamone, C; Hull, MA; Liverani, E; Munarini, A; Scaioli, E, 2015
)
0.89
" The method was successfully applied to a pharmacokinetic study of EPAEE and DHAEE in healthy Chinese volunteers after the oral administration of 4 g omega-3-acid ethyl esters 90 soft capsule."( LC-APCI-MS/MS assay for quantitation of ethyl esters of eicosapentaenoic acid and docosahexaenoic acid in human plasma and its application in a pharmacokinetic study.
Ding, L; Ji, S; Li, L; Xia, Y; Zhao, S, 2020
)
0.8
" The pharmacokinetic results of this study were also compared with those of available data for Western populations."( Pharmacokinetics of Single and Multiple Doses of Omega-3 Carboxylic Acids in Healthy Chinese Subjects: A Phase I, Open-Label Study.
Chen, X; Jing, S; Lin, Y; Miao, R; Nilsson, C; Zhang, Z, 2020
)
0.56

Compound-Compound Interactions

The effects of gamma-linolenic acid-rich borage oil (BO) in combination with different marine oils, namely an eicosapentaenoic acid (EPA) rich oil (MO) or a DHA-rich oil (TO), on tissue fatty acid composition and prostaglandin production were investigated in turbot.

ExcerptReferenceRelevance
"The effects of gamma-linolenic acid-rich borage oil (BO), in combination with different marine oils, namely an eicosapentaenoic acid (EPA) rich oil (MO) or a DHA-rich oil (TO), on tissue fatty acid composition and prostaglandin production were investigated in turbot, a species which lacks appreciable delta5 fatty acyl desaturase activity."( Effects of dietary gamma-linolenic acid-rich borage oil combined with marine fish oils on tissue phospholipid fatty acid composition and production of prostaglandins E and F of the 1-, 2- and 3-series in a marine fish deficient in delta5 fatty acyl desatu
Bell, JG; Farndale, BM; Sargent, JR; Tocher, DR, 1997
)
0.51
" Dietary intake of genistein in combination with EPA may be beneficial for breast cancer control."( Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines.
Hioki, K; Kiyozuka, Y; Nakagawa, H; Tsubura, A; Tsuta, K; Tsutsui, Y; Uemura, Y; Yamamoto, D, 2000
)
0.55
"Bladder cancer cells were exposed to MeEPA in combination with epirubicin or mitomycin."( Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin.
Cooper, AJ; Harris, NM; Lwaleed, BA; Mackie, SJ; Sharma, DM, 2006
)
0.74
" Hence administering omega-3 polyunsaturated fatty acids can enhance synaptic membrane levels in gerbils, and may do so in patients with neurodegenerative diseases, especially when given with a uridine source, while the omega-6 polyunsaturated fatty acid arachidonic acid is ineffective."( Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils.
Cansev, M; Wurtman, RJ, 2007
)
0.59
" The aim of the present study was to investigate whether long-chain n-3 PUFA (LCn-3PUFA), combined with a very-low-energy diet (VLED), facilitated weight loss and weight maintenance, and improvements in blood lipids and inflammatory mediators."( Dietary supplementation with n-3 PUFA does not promote weight loss when combined with a very-low-energy diet.
Garg, ML; Munro, IA, 2012
)
0.38
" Additional diets included 10 g kg(-1) DHA in combination with 10 g kg(-1) of either eicosapentaenoic acid (EPA; 20:5n-3) or arachidonic acid (ARA; 20:4n-6), and a diet containing 5 g kg(-1) each of DHA and EPA."( Influence of dietary docosahexaenoic acid in combination with other long-chain polyunsaturated fatty acids on expression of biosynthesis genes and phospholipid fatty acid compositions in tissues of post-smolt Atlantic salmon (Salmo salar).
Betancor, MB; Glencross, BD; Howarth, FJ; Tocher, DR,
)
0.36
" EPA inhibition was enhanced when combined with atorvastatin metabolite at low equimolar concentrations."( Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.
Jacob, RF; Mason, RP; Sherratt, SC, 2016
)
1.88
" To test the hypothesis that an n-3 (ω-3) polyunsaturated fatty acid-rich food could synergize with other, largely polyphenol-rich foods by producing greater reductions in metabolic disease conditions, the intake of English walnuts was evaluated in combination with 9 other whole foods."( Consumption of Walnuts in Combination with Other Whole Foods Produces Physiologic, Metabolic, and Gene Expression Changes in Obese C57BL/6J High-Fat-Fed Male Mice.
Adamson, A; Hamilton-Reeves, J; Kinchen, JM; Luo, T; Miranda-Garcia, O; Shay, NF; Sullivan, DK, 2016
)
0.43
" The addition of a second whole food in combination with walnuts produced other changes in metabolite concentrations and gene expression patterns and other physiologic markers."( Consumption of Walnuts in Combination with Other Whole Foods Produces Physiologic, Metabolic, and Gene Expression Changes in Obese C57BL/6J High-Fat-Fed Male Mice.
Adamson, A; Hamilton-Reeves, J; Kinchen, JM; Luo, T; Miranda-Garcia, O; Shay, NF; Sullivan, DK, 2016
)
0.43
" In this study, the effects of pathological (100ng/ml) or supra-pathological (10μg/ml) concentrations of leptin alone or in combination with IL1β on cartilage metabolisms were studied in porcine cartilage explant."( Leptin alone and in combination with interleukin-1-beta induced cartilage degradation potentially inhibited by EPA and DHA.
Boonmaleerat, K; Kongtawelert, P; Phitak, T; Pothacharoen, P; Pruksakorn, D, 2018
)
0.48
" However, against solid tumors, EPA as a monotherapy is clinically ineffective; thus, we sought to develop a novel targeted drug combination to bolster its therapeutic action against TNBC."( Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.
Chapkin, RS; Eckhardt, BL; Fan, YY; Levental, KR; Qi, Y; Tan, L; Torres-Adorno, AM; Ueno, NT; Vitrac, H; Yang, P, 2019
)
1.96
" However, few studies have been conducted examining anti-tumor effects of nutritional supplements (NS) containing Se and EPA/DHA in combination with anti-cancer agents, such as taxol (Tax), adriamycin (Adr), and avastin (Ava)."( Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.
Chen, PC; Chung, CH; Guo, CH; Henning, SM; Hsia, S; Hsu, GW; Li, Z; Lin, YC; Peng, CL; Shih, MY, 2021
)
0.62
" However, concomitant use of bortezomib in combination with either of DHA or EPA decreased the cell death induced by bortezomib, indicating that timing of coincubation is important for the effects on chemosensitivity."( The efficacy of bortezomib in human multiple myeloma cells is enhanced by combination with omega-3 fatty acids DHA and EPA: Timing is essential.
Chen, J; Garssen, J; Redegeld, F, 2021
)
0.62
"The present study provides novel evidence for the anticancer effects of DHA and EPA, and highlights their rational utilization in combination with bortezomib to achieve improved therapeutic outcome for MM."( The efficacy of bortezomib in human multiple myeloma cells is enhanced by combination with omega-3 fatty acids DHA and EPA: Timing is essential.
Chen, J; Garssen, J; Redegeld, F, 2021
)
0.62
"The aim of this study was to estimate the cost-effectiveness, from the perspective of the Australian public healthcare system, of icosapent ethyl in combination with statin therapy compared with statin alone for the prevention of cardiovascular disease."( The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi, Z; Liew, D; Ofori-Asenso, R; Owen, A; Zomer, E, 2021
)
0.62
"A Markov model populated with data from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial was designed to predict the effectiveness and costs of icosapent ethyl in combination with statins compared with statins alone over a 20-year time horizon."( The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi, Z; Liew, D; Ofori-Asenso, R; Owen, A; Zomer, E, 2021
)
0.62
"Compared with statin alone, icosapent ethyl in combination with statin therapy is likely to be cost-effective in the prevention of cardiovascular disease assuming a willingness-to-pay threshold of AUD50,000 per QALY gained, especially in the secondary preventive setting."( The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Ademi, Z; Liew, D; Ofori-Asenso, R; Owen, A; Zomer, E, 2021
)
0.62
"To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service."( Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T, 2022
)
0.72
"Epidemiological and clinical evidence suggests that high-dose intake of omega 3 fatty acids (n-3 FA) have a favorable role in altering serum triglycerides (TG) and non-high density lipoprotein cholesterol (non-HDL-C) when combined with statins in hyperlipidemic patients."( N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
Dogay Us, G; Mushtaq, S, 2022
)
0.72

Bioavailability

The systemic bioavailability of free fatty acid (FFA) forms of eicosapentaenoic acid (EPA) compared with ethyl ester (EE) forms is dependent on the presence of intestinal lipases and is highest during consumption of high-fat meals.

ExcerptReferenceRelevance
" Data were scrutinized for bioavailability in order to distinguish between the efficiency of the two preparations."( Pharmacokinetics of omega-3-fatty acids during ingestion of fish oil preparations.
Baldamus, CA; Marsen, TA; Oette, K; Pollok, M, 1992
)
0.28
" Thus, n-3 fatty acids are well absorbed after one dose of either tuna or fish oil but EPA absorption appears to be more efficient from tuna."( Comparison of the absorption and effect on platelet function of a single dose of n-3 fatty acids given as fish or fish oil.
Pasternak, RC; Sacks, FM; Silverman, DI; Ware, JA, 1991
)
0.28
" Ethyl esters alone were well absorbed and produced similar n-3 fatty acid responses in plasma triglycerides and chylomicrons."( Absorption of the n-3 eicosapentaenoic and docosahexaenoic acids as ethyl esters and triglycerides by humans.
Barstad, L; Connor, WE; Hatcher, L; Nordøy, A, 1991
)
0.28
"Comparative Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid from Triglycerides, Free Fatty Acids and Ethyl Esters in Volunteers."( [Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers].
Beckermann, B; Beneke, M; Seitz, I, 1990
)
0.85
" UFAs were found to be well absorbed into tumor tissues after oral administration, causing marked changes in relative levels, the arachidonic acid (AA) content, in particular, being markedly decreased by treatment with DHA or EPA, but not with DHA plus EPA or with DHA plus LA."( Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities.
Araki, E; Asamoto, M; Iigo, M; Ishikawa, C; Kuhara, T; Kunimoto, T; Moore, MA; Suzuki, I; Tsuda, H; Yazawa, K, 1997
)
0.3
" To assess the effect of Entrox coating on the short-term bioavailability of ALA administered in the form of ALA-rich Perilla seed oil, 12 healthy subjects (6 males and 6 females) received in a random order Entrox-coated and non-coated ALA formulations, each as a single 6g dose separated by a 3-week washout period."( Bioavailability of omega-3 essential fatty acids from perilla seed oil.
Deutsch, L; Dresser, GK; Khalil, W; Kurowska, EM; Vachon, D, 2003
)
0.32
" Cyclooxygenase (COX) converts EPA intracellularly into various inflammatory mediators that may affect the bioavailability of this fatty acid for inducing apoptosis in the cancer cells."( Synergistic action of piroxicam on the eicosapentaenoic acid-induced apoptosis is associated with enhanced down-regulation of anti-apoptotic Bcl-2 expression but not promoted activation of pro-apoptotic Bid protein.
Chiu, LC; Ooi, VE; Tong, KF, 2004
)
0.59
" In the present study, the effect of LCPUFA, as provided in evening primrose oil, fish and tuna oils, on calcium bioavailability was investigated."( Is docosahexaenoic acid more effective than eicosapentaenoic acid for increasing calcium bioavailability?
Kruger, MC; Schollum, LM, 2005
)
0.59
"Improving the bioavailability of beta-carotene is vital to manage vitamin A deficiency."( Micellar oleic and eicosapentaenoic acid but not linoleic acid influences the beta-carotene uptake and its cleavage into retinol in rats.
Baskaran, V; Krishnakantha, TP; Lakshminarayana, R; Raju, M, 2006
)
0.66
" Unlike fish-sourced oils, the bioavailability of DHA from vegetarian-sourced (algal) oils has not been formally assessed."( Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food.
Arterburn, LM; Bailey-Hall, E; Chung, G; Hamersley, J; Hoffman, JP; McCarthy, D; Oken, HA; Rom, D, 2007
)
0.34
" However, before extensive work can be undertaken in clinical populations to determine its efficacy, basic information on ALA bioavailability from flaxseed and the physiological effects of its ingestion need to be examined."( Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed.
Austria, JA; Chahine, MN; Dupasquier, CM; Edel, AL; Malcolmson, LJ; Pierce, GN; Richard, MN, 2008
)
0.35
"The purpose of this study, therefore, was to determine the bioavailability of ALA when the flaxseed was ingested in the form of whole seed, milled seed or as flaxseed oil."( Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed.
Austria, JA; Chahine, MN; Dupasquier, CM; Edel, AL; Malcolmson, LJ; Pierce, GN; Richard, MN, 2008
)
0.35
"To assess the comparative pharmacokinetic profile and bioavailability of docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) after multiple-dose administration of a new oral formulation (test formulation) and a commercially available reference formulation in healthy subjects."( Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers.
Di Stefano, AF; Doig, MV; Perucca, E; Rusca, A; Scarsi, C, 2009
)
0.79
"The two formulations tested were similarly effective in increasing DHA and EPA concentrations in plasma and lysed whole blood, and showed comparable bioavailability for both active components."( Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers.
Di Stefano, AF; Doig, MV; Perucca, E; Rusca, A; Scarsi, C, 2009
)
0.57
"Benefits of eicosapentaenoic acid (EPA) can be enhanced by raising their bioavailability through microencapsulation."( Enhanced bioavailability of eicosapentaenoic acid from fish oil after encapsulation within plant spore exines as microcapsules.
Atkin, SL; Bell, JG; Diego-Taboada, A; Mackenzie, G; Wakil, A, 2010
)
1.03
" Bioavailability of EPA+DHA from re-esterified triglycerides was superior (124%) compared with natural fish oil, whereas the bioavailability from ethyl esters was inferior (73%)."( Bioavailability of marine n-3 fatty acid formulations.
Aardestrup, I; Dyerberg, J; Madsen, P; Møller, JM; Schmidt, EB, 2010
)
0.36
" Taken together, these findings indicate that CYP-dependent signaling pathways are highly susceptible to changes in the relative bioavailability of the different PUFAs and may provide novel insight into the complex mechanisms that link essential dietary fatty acids to the development of cardiovascular disease."( Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids.
Konkel, A; Schunck, WH, 2011
)
0.37
" Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared."( Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil.
Hahn, A; Meyer, H; Neubronner, J; Schneider, I; Schuchardt, JP; von Schacky, C, 2011
)
0.37
"Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil)."( Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil.
Hahn, A; Meyer, H; Neubronner, J; Schneider, I; Schuchardt, JP; von Schacky, C, 2011
)
0.37
" Overall the fundamental knowledge generated within the past decade indicates that orally bioavailable small molecule inhibitors of sEH may find a place in the treatment of a number of diverse painful conditions including inflammatory and neuropathic pain."( Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.
Hammock, BD; Inceoglu, B; Wagner, K, 2011
)
0.37
" • Bioavailability evaluations of ethyl ester preparations are hampered by the difficulty in achieving similar concentrations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the preparations being compared."( Bioequivalence of two omega-3 fatty acid ethyl ester formulations: a case of clinical pharmacology of dietary supplements.
Galli, C; Maggi, FM; Risé, P; Sirtori, CR, 2012
)
0.58
" Intriguingly, recent studies have demonstrated that ω-3-PUFAs improve the function of vascular endothelium by enhancing the generation and bioavailability of endothelium-derived relaxing factor (nitric oxide) through upregulation and activation of endothelial nitric oxide synthase (eNOS)."( Fish oil and vascular endothelial protection: bench to bedside.
Balakumar, P; Taneja, G, 2012
)
0.38
" Lipemia and hepatosteatosis were suppressed more in response to dietary phospholipids, in correlation with better bioavailability of DHA and EPA, and a higher DHA accumulation in the liver, white adipose tissue (WAT), and muscle phospholipids."( Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids.
Balvers, MG; Bryhn, M; Haraldsson, GG; Jelenik, T; Jilkova, ZM; Kopecky, J; Kristinsson, B; Kuda, O; Magnusson, Y; Medrikova, D; Rossmeisl, M; Sjövall, P; Stankova, B; Stoknes, I; Svensen, H; Tvrzicka, E; Verhoeckx, KC, 2012
)
0.38
"The formation of nanoparticles from eicosapentaenoic acid (EPA) is crucial to improving EPA's bioavailability and pharmacological properties, and widening its use in biomedical fields."( Elevated anti-inflammatory effects of eicosapentaenoic acid based self-aggregated glycol chitosan nanoparticles.
Jeong, HJ; Kim, DW; Kim, J; Lee, CM; Lee, KY, 2012
)
0.92
"In the present study, we used a preclinical model of induced lipolytic enzyme insufficiency, and hypothesized that the use of monoacylglycerols (MAG) will enhance their bioavailability and delivery to the tissues."( Benefits of structured and free monoacylglycerols to deliver eicosapentaenoic (EPA) in a model of lipid malabsorption.
Cruz-Hernandez, C; Destaillats, F; Dionisi, F; Masserey-Elmelegy, I; Moulin, J; Oliveira, M; Thakkar, SK, 2012
)
0.38
", Princeton, NJ) was developed to maximize EPA and DHA bioavailability during a low-fat diet."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
"To compare the relative bioavailability of EPA and DHA from single 4-gram doses of OM-3 FFA and a prescription OM-3 EE (Lovaza(®), GlaxoSmithKline, Research Triangle Park, NC)."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
"This was a randomized, open-label, single dose, 4-way crossover, bioavailability study of OM-3 FFA and OM-3 EE administered during periods of low-fat and high-fat consumption to 54 overweight adults."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
"During a low-fat consumption period, the OM-3 FFA formulation provided dramatically improved bioavailability over the OM-3 EE formulation in overweight subjects."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
", NJ, USA) is a novel ω-3 free fatty acid formulation, developed to maximize eicosapentenoic acid and docosahexenoic acid bioavailability with low-fat diets, suggesting a potential therapeutic advantage compared with ω-3-acid ethyl esters in the treatment of patients with hypertriglyceridemia."( Epanova(®) and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy.
Kataoka, Y; Nicholls, SJ; Puri, R; Uno, K, 2013
)
0.39
" The effects of a highly bioavailable emulsified preparation on an overweight young adult population are less well known."( A randomized trial of fish oil omega-3 fatty acids on arterial health, inflammation, and metabolic syndrome in a young healthy population.
Collier, SR; McGinn, MC; Root, M; West, KL; Zwetsloot, KA, 2013
)
0.39
" However, the question of omega-3 fatty acids bioavailability has long been disregarded, which may have contributed to the neutral or negative results concerning their effects in several studies."( Bioavailability of long-chain omega-3 fatty acids.
Hahn, A; Schuchardt, JP, 2013
)
0.39
"The systemic bioavailability of free fatty acid (FFA) forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) compared with ethyl ester (EE) forms is dependent on the presence of intestinal lipases and is highest during consumption of high-fat meals."( Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Curcio, D; Davidson, M; Ferber, S; Johnson, J; Kling, D; Marenco, T; Offman, E, 2013
)
0.63
"Due to structural differences, bioavailability of krill oil, a phospholipid based oil, could be higher than fish oil, a triglyceride-based oil, conferring properties that render it more effective than fish oil in increasing omega-3 index and thereby, reducing cardiovascular disease (CVD) risk."( Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil.
Eyal, I; Jones, PJ; Ramprasath, VR; Zchut, S, 2013
)
0.39
" Neutral results of intervention trials can be explained by issues of bioavailability and trial design that surfaced after the trials were initiated."( Omega-3 index and cardiovascular health.
von Schacky, C, 2014
)
0.4
" Also, limited knowledge of the metabolism of dietary bioactives, and therefore of the bioavailability of bioactive ingredients, restricts our ability to identify the most effective dietary regimes to improve platelet function."( Dietary manipulation of platelet function.
Bachmair, EM; de Roos, B; Ostertag, LM; Zhang, X, 2014
)
0.4
" Studies have shown that PL may improve bioavailability of n-3 PUFAs."( Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults.
Berge, RK; Berger, A; Bjørndal, B; Bohov, P; Diehl, BW; Gjerde, J; Innis, SM; Strand, E; Svardal, A, 2014
)
0.4
" The bioavailability of currently available OM3 ethyl ester drugs is limited by their need for hydrolysis by pancreatic lipases, largely stimulated by dietary fat, prior to intestinal absorption."( Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
Davidson, MH; Kling, D; Maki, KC; Phillips, AK, 2014
)
0.4
" Bioavailability is important to achieve efficacy."( Bioavailability of long-chain n-3 fatty acids from enriched meals and from microencapsulated powder.
Hinriksdottir, HH; Jonsdottir, VL; Martinsdottir, E; Ramel, A; Sveinsdottir, K, 2015
)
0.42
"Bioavailability of LC n-3 PUFAs in encapsulated powder is very similar to the bioavailability of LC n-3 PUFAs in ready-to-eat meals enriched with liquid fish oil."( Bioavailability of long-chain n-3 fatty acids from enriched meals and from microencapsulated powder.
Hinriksdottir, HH; Jonsdottir, VL; Martinsdottir, E; Ramel, A; Sveinsdottir, K, 2015
)
0.42
" However, the significant difference in efficacy observed in various conditions with different dosages seems to be at least partly related to the large discrepancy in quality of the product and to the bioavailability of the omega-3 PUFA."( Do we need 'new' omega-3 polyunsaturated fatty acids formulations?
Borghi, C; Cicero, AF; Morbini, M, 2015
)
0.42
" The FFA form of EPA and DHA is associated with higher bioavailability than other forms of ω3 fatty acids, potentially resulting in efficacy at lower doses and less dependence on meal relationship."( ω-3 carboxylic acids for hypertriglyceridemia.
Roth, EM, 2015
)
0.42
"The high complexity of n-3 fatty acids absorption process, along with the huge amount of endogenous fraction, makes bioavailability studies with these agents very challenging and deserving special consideration."( The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids.
Levesque, A; Lisi, L; Navarra, P; Scarsi, C, 2015
)
0.42
" The aim of the present study was to compare the bioavailability of n-3 FA delivered as two microencapsulated fish oil-formulated powders or fish oil gel capsules (FOGC) taken with a flavoured milk in healthy participants."( Bioequivalence of n-3 fatty acids from microencapsulated fish oil formulations in human subjects.
Abeywardena, MY; Augustin, MA; Lockett, TJ; Mano, MT; Patten, GS; Royle, PJ; Sanguansri, L, 2015
)
0.42
" The difference in the chemical binding of EPA and DHA has been suggested to affect their bioavailability, but little is known on bioavailability of EPA and DHA in krill meal."( Bioavailability of fatty acids from krill oil, krill meal and fish oil in healthy subjects--a randomized, single-dose, cross-over trial.
Bruheim, I; Köhler, A; Niskanen, T; Sarkkinen, E; Tapola, N, 2015
)
0.42
"EPA and DHA in krill oil had a higher 72-hour bioavailability than in krill meal or fish oil."( Bioavailability of fatty acids from krill oil, krill meal and fish oil in healthy subjects--a randomized, single-dose, cross-over trial.
Bruheim, I; Köhler, A; Niskanen, T; Sarkkinen, E; Tapola, N, 2015
)
0.42
" The aim of this study was to compare the bioavailability and metabolic fate (absorption, β-oxidation and tissue deposition) of n-3 fatty acids originating from krill oil (phospholipid-rich) or fish oil (TAG-rich) in rats of both sexes using the whole-body fatty acid balance method."( Metabolic fate (absorption, β-oxidation and deposition) of long-chain n-3 fatty acids is affected by sex and by the oil source (krill oil or fish oil) in the rat.
Ghasemifard, S; Hermon, K; Sinclair, AJ; Turchini, GM, 2015
)
0.42
" Recently, conflicting information was published on the relative bioavailability of these omega-3 supplements."( Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study.
Bailey-Hall, E; Kralovec, J; Salem, N; Smeberg, V; Stark, JG; Yurko-Mauro, K, 2015
)
0.85
"052 and bioavailability differed by < 24 % between the groups."( Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study.
Bailey-Hall, E; Kralovec, J; Salem, N; Smeberg, V; Stark, JG; Yurko-Mauro, K, 2015
)
0.85
"Similar plasma and RBC levels of EPA + DHA were achieved across fish oil and krill oil products when matched for dose, EPA, and DHA concentrations in this four week study, indicating comparable oral bioavailability irrespective of formulation."( Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study.
Bailey-Hall, E; Kralovec, J; Salem, N; Smeberg, V; Stark, JG; Yurko-Mauro, K, 2015
)
0.85
"Studies on bioavailability of EPA and DHA from KO and FO in humans and animals are limited and the interpretation is difficult, as different amounts of EPA and DHA have been used, duration of intervention differs, and different study groups have been included."( Comparison of bioavailability of krill oil versus fish oil and health effect.
Holven, KB; Ulven, SM, 2015
)
0.42
"There seems to be a difference in bioavailability of EPA and DHA after intake of KO and FO, but more studies are needed before a firm conclusion can be made."( Comparison of bioavailability of krill oil versus fish oil and health effect.
Holven, KB; Ulven, SM, 2015
)
0.42
" The objective of the present trial was to test the effect of different amounts of PL in krill oil on the bioavailability of EPA and DHA, assessed as the rate of increase of n-3 PUFA in plasma and RBC, in healthy volunteers."( Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil.
Eyal, I; Jones, PJ; Ramprasath, VR; Shafat, I; Zchut, S, 2015
)
0.42
"The results indicate that krill oil with higher PL levels could lead to enhanced bioavailability of n-3 PUFA compared to krill oil with lower PL levels."( Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil.
Eyal, I; Jones, PJ; Ramprasath, VR; Shafat, I; Zchut, S, 2015
)
0.42
" Further, relations between ALOX5 and disease outcomes may be enhanced or attenuated depending on the bioavailability of 5-lipoxygenase enzyme substrates."( 5-Lipoxygenase Gene Variants Are Not Associated With Atherosclerosis or Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis Cohort.
Cao, J; Guan, W; Liang, S; Rich, SS; Steffen, BT; Tsai, MY; Weir, NL, 2016
)
0.43
"This randomized, single-blind, crossover trial assessed the bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) from two different sources, each examined over a 12h period following consumption of a single serving and after 2-weeks of daily supplementation."( Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols.
Berger, A; Cook, CM; Hallaråker, H; Innis, SM; Kelley, KM; Maki, KC; Sanoshy, KD; Sæbø, PC, 2016
)
0.66
" OM3CA bioavailability (area under the plasma concentration-time curve from zero to the last measurable concentration) is up to 4-fold greater than that of OM3FA ethyl esters, and unlike ethyl esters, the absorption of OM3CA is not dependent on pancreatic lipase hydrolysis."( The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Anzalone, D; Backes, J; Catini, J; Hilleman, D, 2016
)
0.43
" Food intake is known to affect the bioavailability of ethyl ester fatty acid formulations."( Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial.
Kim, H; Lundström, T; Nilsson, C; Noda, Y; Shimada, H; Yajima, T, 2017
)
0.46
"The timing of OM3-CA administration relative to food intake influences the systemic bioavailability of EPA and DHA in healthy Japanese male subjects."( Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial.
Kim, H; Lundström, T; Nilsson, C; Noda, Y; Shimada, H; Yajima, T, 2017
)
0.46
"Two separate single dose, crossover studies were conducted to determine the relative bioavailability of omega-3-acid EE concentrate, either as a novel SMEDS formulation (PRF-021) or as control, in healthy fasted male and female adults at two dose levels (Study 1 "low dose": 630 mg EPA + DHA in PRF-021 vs."( A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate.
Haram, EM; Hustvedt, SO; Moritz, JM; Nyheim, H; Qin, Y, 2017
)
0.46
" Endothelial dysfunction represents an early but reversible step in atherosclerosis and is characterized by a reduction in the bioavailability of NO."( Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin.
Dawoud, H; Jacob, RF; Malinski, T; Mason, RP; Sherratt, SCR, 2018
)
1.92
" The mechanism of Krill oil function is not clear yet and research reports on the absorption rate of the phospholipids of krill oil in the blood and brain are very poor."( Absorption rate of krill oil and fish oil in blood and brain of rats.
Ahn, SH; Han, SH; Lim, SJ; Park, HR; Ryu, YM; Suh, HJ, 2018
)
0.48
"We studied the effect of oral short-term and long-term administration of Krill oils (KOs) on bioavailability in the blood and brain of rats."( Absorption rate of krill oil and fish oil in blood and brain of rats.
Ahn, SH; Han, SH; Lim, SJ; Park, HR; Ryu, YM; Suh, HJ, 2018
)
0.48
" Here, we studied safety and bioavailability of algae nutrients in mice."( Bioavailability and Safety of Nutrients from the Microalgae
Bischoff, SC; Briviba, K; Derwenskus, F; Gille, A; Louis, S; Neumann, U; Schmid-Staiger, U, 2018
)
0.48
" Dietary supplements are available for consumers wishing to increase their intakes, but many of these are in ethyl ester formulations from which EPA and DHA are poorly absorbed when consumed without a meal containing dietary fat."( Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates.
Dicklin, MR; Maki, KC, 2019
)
0.51
"The development of absorption enhancement technology to increase bioavailability of long-chain omega-3 fatty acids has important implications for studies on the health effects of dietary supplement and pharmaceutical products containing EPA and/or DHA."( Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates.
Dicklin, MR; Maki, KC, 2019
)
0.51
"The physiological efficacy of nutraceuticals is dependent on their physicochemical nature and bioavailability across biological barriers."( Effects of nano-sizing on lipid bioaccessibility and ex vivo bioavailability from EPA-DHA rich oil in water nanoemulsion.
Dey, S; Dey, TK; Dhar, P; Ghosh, M; Koley, H, 2019
)
0.51
" AOCED's bioavailability as a source of DHA and EPA in dogs was demonstrated by the increased plasma concentrations of these nutritional lipids."( Safety of a novel feed ingredient, Algal Oil containing EPA and DHA, in a gestation-lactation-growth feeding study in Beagle dogs.
Bailey-Hall, E; Dahms, I; Karagiannis, A; Parenteau, A; Roos, F; Sylvester, E; Wilson, J; Yu, S, 2019
)
0.51
" Much attention has been focused on the bioavailability and health benefits that are influenced by the type and esterified form of dietary fatty acids."( Health benefits of dietary marine DHA/EPA-enriched glycerophospholipids.
Wang, YM; Xu, J; Xue, CH; Zhang, TT, 2019
)
0.51
" Moreover, the phospholipid bound nature of fatty acids found in KO improves bioavailability and efficiency of absorption, thus supporting the belief that KO may offer a superior method of dietary n-3 delivery."( Can krill oil be of use for counteracting neuroinflammatory processes induced by high fat diet and aging?
Andraka, JM; Marchalant, Y; Sharma, N, 2020
)
0.56
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Application of intelligent formulation design has the ability to address the poor bioavailability and improve the fasted state bioavailability of fish oils."( A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults.
Bremmell, KE; Briskey, D; Mallard, A; Meola, TR; Prestidge, CA; Rao, A, 2020
)
0.56
" While their mechanism of action, bioavailability in the blood, and their efficacy for clinical use forms an active area of research, they are found widely administered as marine animal-based supplements like fish oil and krill oil to promote health."( Dietary Bioactive Fatty Acids as Modulators of Immune Function: Implications on Human Health.
Brophy, DF; Carbone, S; Contaifer, D; Kumar, NG; Madurantakam, P; Price, ET; Van Tassell, B; Wijesinghe, DS, 2019
)
0.51
" Plasma levels of EPA and DHA were dose-dependently increased in both generations, demonstrating bioavailability of the fatty acids."( Safety of Algal Oil Containing EPA and DHA in cats during gestation, lactation and growth.
Bailey-Hall, E; Dahms, I; Karagiannis, A; Roos, F; Sylvester, E; Vuorinen, A; Wilson, J; Yu, S, 2020
)
0.56
"Two trials separately measured the bioavailability and impact on inflammation of a supplement taken daily containing 510 mg Docosahexaenoic acid (DHA), 344 mg Eicosapentaenoic acid (EPA), and 1000 IU of vitamin D (25-hydroxyvitamin D; 25(OH)D), for healthy and Crohn's disease (CD) populations."( Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations.
Brennan Laing, B; Cavadino, A; Ellett, S; Ferguson, LR, 2020
)
0.75
"The in vitro dissolution characteristics, oral bioavailability and 48 h plasma profiles of EPA and DHA (as triacylglycerides) of Lys-FFA, relative to a commercially available oil-based EE supplement."( In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA.
Balvers, M; Bosi, R; Diepeveen-de Bruin, M; Headley, L; Manusama, K; Schwarm, M; Witkamp, R, 2021
)
0.62
"This first-in-man study of Lys-FFA demonstrated rapid absorption of EPA and DHA and a considerably higher bioavailability compared to an EE supplement under fasting conditions."( In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA.
Balvers, M; Bosi, R; Diepeveen-de Bruin, M; Headley, L; Manusama, K; Schwarm, M; Witkamp, R, 2021
)
0.62
" However, most previous studies have compared only the long-term bioavailability of fish versus fish oil and have used commercial sources of fish oil."( Salmon food matrix influences digestion and bioavailability of long-chain omega-3 polyunsaturated fatty acids.
Ahmed Nasef, N; Ali, A; Dave, A; Garg, M; Golding, M; Singh, H; Zhu, P, 2021
)
0.62
"There are conflicting findings over the bioavailability of long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) from krill oil (KO) compared with fish oil (FO) in short- and long-term studies."( Enrichment of n-3 containing ether phospholipids in plasma after 30 days of krill oil compared with fish oil supplementation.
Sinclair, AJ; Su, XQ; Sung, HH, 2022
)
0.72
" Recently, supplementation with structured forms of EPA and DHA, which can be derived natural forms or targeted structures, have proven enhanced bioavailability and powerful benefits."( Structured Long-Chain Omega-3 Fatty Acids for Improvement of Cognitive Function during Aging.
Arola, L; Caimari, A; Escoté, X; Mora, I; Puiggròs, F, 2022
)
0.72
" This study aimed to test the bioavailability of the oil derived from basil seeds and its effects on different physiological parameters using 7-15% dietary inclusion levels."( Bioavailability and biotransformation of linolenic acid from basil seed oil as a novel source of omega-3 fatty acids tested on a rat experimental model.
Bermúdez, F; Galisteo, M; Guzmán, A; López-Jurado, M; Martínez, R; Melguizo, C; Mesas, C; Porres, JM; Prados, J, 2022
)
0.72
" The findings provided a nanoemulsion delivery system to increase the bioavailability of nobiletin in vitro and in vivo."( Characterization, stability, digestion and absorption of a nobiletin nanoemulsion using DHA-enriched phosphatidylcholine as an emulsifier in vivo and in vitro.
Huang, QR; Ju, SN; Shi, HH; Wang, YM; Xue, CH; Yang, JY; Zhang, TT; Zhao, YC, 2022
)
0.72
" Finally, a summary of current advanced strategies for dealing with the low oxidative stability and low bioavailability of EPA-EE is presented."( Highly Valuable Fish Oil: Formation Process, Enrichment, Subsequent Utilization, and Storage of Eicosapentaenoic Acid Ethyl Esters.
Jin, Q; Karrar, E; Wang, X; Wu, G; Yi, M; You, Y; Zhang, H; Zhang, L; Zhang, Y, 2023
)
1.13
"The bioavailability of long-chain omega-3 polyunsaturated fatty acids (n3 PUFA) can be affected by the form in which they are bound."( Equal bioavailability of omega-3 PUFA from Calanus oil, fish oil and krill oil: A 12-week randomized parallel study.
Burhop, M; Hahn, A; Schuchardt, JP; Vosskötter, F, 2023
)
0.91
"This randomized, double-blind, crossover study evaluated the bioavailability of eicosapentaenoic and docosahexaenoic acids (EPA+DHA) in a phospholipid-enhanced fish oil (PEFO) product versus a krill oil (KO) product (337 versus 206 mg EPA+DHA/1 g capsule) in healthy adults (N = 24)."( Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study.
Guarneiri, LL; Maki, KC; Wilcox, ML, 2023
)
0.91
" DHA/EPA in the form of phospholipids demonstrates higher bioavailability than triglyceride or ethyl ester (EE), but their effects on the lipidome and metabolic changes during obesity are still unknown."( Dietary Eicosapentaenoic Acid Containing Phosphoethanolamine Plasmalogens Remodels the Lipidome of White Adipose Tissue and Suppresses High-Fat Diet Induced Obesity in Mice.
Cong, P; Ding, L; Guo, H; Mao, X; Wang, Y; Xu, J; Xue, C; Yang, J; Zhang, T, 2023
)
1.34

Dosage Studied

Evidence might support the use of omega-3 fatty acids (preferably docosahexaenoic acid and eicosapentaenoic Acid) for lowering blood pressure. The strength and shape of the dose-response relationship remains unclear.

ExcerptRelevanceReference
" EPA levels rose in the three dosage groups by factors 7, 9 and 14, respectively, if compared to values upon placebo."( Fish oil treatment and apolipoprotein(a).
Hanisch, M; Klör, HU; Lelieur, I; Lodde, A; Luley, C; Vohwinkel, M; Wieland, H, 1992
)
0.28
" Results of previous studies have been controversial, depending on the dosage of fish oil and the phenotypic cause of the hyperlipoproteinaemia."( Influence of fish oil on blood lipids in coronary artery disease.
Nikkilä, M, 1991
)
0.28
" With this dosage of fish oil no relevant variations in glycemic control, insulin secretion and insulin sensitivity occurred."( A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients.
Annuzzi, G; Capaldo, B; Di Marino, L; Iovine, C; Marotta, G; Riccardi, G; Rivellese, A, 1991
)
0.28
"A dose-response study of dietary fish oil supplementation on platelet adhesion was performed in three groups of five normal individuals each."( Dose response of dietary fish oil supplementations on platelet adhesion.
Li, XL; Steiner, M,
)
0.13
" Lymph was collected from a thoracic duct cannula for 24 hr after dosing via an indwelling duodenal catheter."( Recovery of fish oil-derived fatty acids in lymph of thoracic duct-cannulated Wistar rats.
Hoadley, J; Morehouse, KM; Reicks, M; Satchithanandam, S, 1990
)
0.28
" The anti-aggregatory, anti-thrombotic and anti-inflammatory properties of omega 3 fatty acids have been confirmed, and a dose-response curve is emerging."( Summary of the NATO advanced research workshop on dietary omega 3 and omega 6 fatty acids: biological effects and nutritional essentiality.
Simopoulos, AP, 1989
)
0.28
" When the results should confirm themselves in long-term studies, a mackerel diet in practicable dosage can be recommended as non-medicamentous treatment of moderate hypertension."( [Changes in blood pressure and serum lipids with fish diets in patients with mild essential hypertension].
Gödicke, W; Hartrodt, W; Mest, HJ; Naumann, E; Richter-Heinrich, E; Singer, P; Taube, C; Voigt, S; Wirth, M, 1986
)
0.27
" The dose-response curves of NA were shifted to the right."( Vasoconstriction induced by noradrenaline and angiotensin II is antagonized by eicosapentaenoic acid independent of formation of trienoic eicosanoids.
Juan, H; Sametz, W, 1986
)
0.5
" The same dosage of maxEPA also resulted in a significant increase in erythrocyte deformability and a concomitant reduction in whole blood viscosity."( The effects of dietary omega-3 polyunsaturated fatty acids on erythrocyte membrane phospholipids, erythrocyte deformability and blood viscosity in healthy volunteers.
Cartwright, IJ; Galloway, JH; Greaves, M; Pockley, AG; Preston, FE, 1985
)
0.27
" The article contains practical recommendations concerning administration of marine products, methods of their conditioning, and also medical and prophylactic dosage of EPA-DHA."( [The use of marine products in the prevention and treatment of vascular diseases of the heart and brain].
Ter-Karapetian, VA, 1994
)
0.29
" In contrast, the dose-response curve for thrombin-induced intracellular free platelet calcium was not altered by the fish oil enriched diet."( Different effects of eicosapentaenoic acid and olive oil on blood pressure, intracellular free platelet calcium, and plasma lipids in patients with essential hypertension.
Haller, H; Passfall, J; Philipp, T; Quass, P; Thiede, M; Woermann, F, 1993
)
0.6
" Patients were instructed to slowly reduce their NSAID dosage providing there was no worsening of their symptoms."( Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study.
Belch, JJ; Lau, CS; Morley, KD, 1993
)
0.29
" The decrease from pre-administration values was significant for patients with abnormal values in both dosage groups."( [The effect on changes in serum lipids and factors that may affect those changes after administration of icosapentaenoic acid ethyl ester].
Aoyama, T; Saga, T; Takekoshi, T, 1993
)
0.29
" Differences were tested by analysis of covariance of the dose-response curves."( Influence of dietary fat on duodenal resistance to acid.
Guarner, F; Lugea, A; Malagelada, JR; Salas, A, 1993
)
0.29
" Dose-response curves (DRC) of U 46619-induced platelet aggregation were analysed by computerized non-linear curve fitting."( Fish oil preparations rich in docosahexaenoic acid modify platelet responsiveness to prostaglandin-endoperoxide/thromboxane A2 receptor agonists.
Clemens, MR; Jaschonek, K; Kirchner, M; Scheurlen, M, 1993
)
0.29
" Experiments examining the influence of Promega dosage indicated that the AA/EPA ratio in neutrophil lipids decreased in a dose-dependent manner."( Dietary n-3 fatty acid effects on neutrophil lipid composition and mediator production. Influence of duration and dosage.
Chilton, FH; Fonteh, AN; Hubbard, WC; Patel, M; Triggiani, M, 1993
)
0.29
" On D28, the patients were randomized into 2 groups: 18 received the drug (fish oil: 30% n-3 PUFA) and 19 received the placebo (olive oil containing only 1% of n-3 PUFA) at a daily dosage of 6 g (i."( Pilot study on n-3 polyunsaturated fatty acids in the treatment of human experimental gingivitis.
Campan, P; Duran, D; Planchand, PO, 1997
)
0.3
" Female Sprague-Dawley rats were dosed with diethylnitrosamine (15 mg/kg) at 24 h of age."( Effect of dietary lipid on gamma-glutamyl transferase-positive foci during hepatocarcinogenesis in rats.
Chen, HW; Ko, JJ; Lii, CK, 1998
)
0.3
" The dose-response curves of Na, K-ATPase activity were all biphasic assuming the presence of two independent sites exhibiting different affinities for ouabain of nM and microM respectively."( Cholesterol and omega-3 fatty acids inhibit Na, K-ATPase activity in human endothelial cells.
Dignat-George, F; Duran, MJ; Gerbi, A; Lévy, S; Maixent, JM; Mayol, V; Sampol, J, 1999
)
0.3
" PIF produced an increased release of [3H]arachidonic acid from prelabeled myoblasts with a dose-response curve parallel to that of protein degradation and with a maximum at 4 nM PIF."( Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid.
Lorite, MJ; Smith, HJ; Tisdale, MJ, 1999
)
0.52
" In addition, we aimed to obtain preliminary information regarding EPA half-life, which is needed to establish an optimal dosing schedule."( Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions.
Dagnelie, PC; Rietveld, T; van den Berg, JW; Wilson, JH; Zuijdgeest-van Leeuwen, SD, 1999
)
0.3
" Dosage was limited by a sensation of fullness, cramping abdominal pain, steatorrhea, and nausea."( Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia.
Barber, MD; Fearon, KC, 2001
)
0.57
" All of the individual items on all 3 rating scales improved with the 1-g/d dosage of ethyl-eicosapentaenoate vs placebo, with strong beneficial effects on items rating depression, anxiety, sleep, lassitude, libido, and suicidality."( A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Horrobin, DF; Peet, M, 2002
)
0.31
"Treatment with ethyl-eicosapentaenoate at a dosage of 1 g/d was effective in treating depression in patients who remained depressed despite adequate standard therapy."( A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Horrobin, DF; Peet, M, 2002
)
0.31
" The immunological effects of more modest doses of n-3 PUFA in human subjects are unclear, dose-response relationships between n-3 PUFA supply and immune function have not been established and whether ALNA has the same effects as its long-chain derivatives is not known."( Comparison of the effects of linseed oil and different doses of fish oil on mononuclear cell function in healthy human subjects.
Calder, PC; Miles, EA; Wallace, FA, 2003
)
0.32
" By the end of the study, 21 (62%) patients were able to reduce their dosage and 13 were able to terminate drug therapy."( Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders.
Graubaum, HJ; Grube, B; Gruenwald, J; Hansen, K,
)
0.13
"EPA was incorporated in a linear dose-response fashion into plasma and mononuclear cell (MNC) phospholipids; incorporation was greater in the older men."( Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men.
Banerjee, T; Calder, PC; Miles, EA; Rees, D; Roynette, CE; Wahle, KW; Wells, SJ, 2006
)
0.64
"Irinotecan hydrochloride (CPT-11), a topoisomerase I inhibitor highly effective for various cancers, has its dosage limited by diffuse mucosal damage with increased prostaglandin (PG) E(2)."( Phospholipid fatty acid composition and diamine oxidase activity of intestinal mucosa from rats treated with irinotecan hydrochloride (CPT-11) under vegetable oil-enriched diets: comparison between perilla oil and corn oil.
Aoyama, M; Fueda, Y; Kishimoto, K; Miyoshi, M; Ohata, A; Ohmae, K; Usami, M,
)
0.13
" However, dose-response relations have not been identified."( Limited effect of eicosapentaenoic acid on T-lymphocyte and natural killer cell numbers and functions in healthy young males.
Banerjee, T; Calder, PC; Miles, EA; Wells, SJ, 2006
)
0.67
"Eicosapentaenoic acid was incorporated in a linear dose-response fashion into mononuclear cell phospholipids."( Limited effect of eicosapentaenoic acid on T-lymphocyte and natural killer cell numbers and functions in healthy young males.
Banerjee, T; Calder, PC; Miles, EA; Wells, SJ, 2006
)
2.11
" Directions for future research include (1) RCTs to confirm the initial trials showing that EPA plus DHA decreases cardiovascular death and additional studies to determine whether this effect is due to EPA, DHA, or the combination; the dosage of the effective components; and whether the mechanism of action in humans is prevention of fatal arrhythmias."( n-3 fatty acids and cardiovascular disease.
Breslow, JL, 2006
)
0.33
" However, dose-response relationships are poorly defined and whether similar effects are seen in young and older subjects is not known."( Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects.
Banerjee, T; Calder, PC; Cazzola, R; Cestaro, B; Goua, M; Miles, EA; Rees, D; Roynette, CE; Russo-Volpe, S; Wahle, KW; Wells, SJ, 2007
)
0.61
" These results may be useful to establish appropriate dosage for omega-3 fatty acid supplementation."( Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids.
Cao, J; Hanson, NQ; Schwichtenberg, KA; Tsai, MY, 2006
)
0.33
" There do not appear to be significant differences in triglyceride-lowering between DHA only and DHA + EPA combination products when dosing is based on DHA."( The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides.
McConnell, KJ; Merenich, JA; Nash, JD; Olson, KL; Schwellenbach, LJ; Stolcpart, RS, 2006
)
0.54
" Freshly excised full-thickness porcine skin in Franz diffusion cells was dosed (both infinite and finite) with simple formulations based on fish oil as source of EPA."( Probing the skin permeation of eicosapentaenoic acid and ketoprofen 2. Comparative depth profiling and metabolism of eicosapentaenoic acid.
Heard, CM; Thomas, CP, 2007
)
0.63
" The dosage was adjusted dependent on the ratio of arachidonic acid (AA) to EPA in the isolated plasma phospholipids at four weeks to reach a level normally found in the Japanese population."( Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder.
Hallowell, EM; Hutchins, HL; Sears, B; Sorgi, PJ, 2007
)
0.34
" A psychiatrist (blind to supplement compliance or dosage modifications) reported significant improvements in behavior (inattention, hyperactivity, oppositional/defiant behavior, and conduct disorder)."( Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder.
Hallowell, EM; Hutchins, HL; Sears, B; Sorgi, PJ, 2007
)
0.34
" Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group but not in the Omacor 8-g dosage group."( Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Bergstralh, EJ; Bibus, DM; Donadio, JV; Grande, JP, 2006
)
0.33
"EPA, DHA can decrease the production of NO, expression of iNOS mRNA and DNA-binding activity of NFkappaB between the dosage of 10microg/ml and 20microg/ml in human peripheral blood monocyte in vitro."( [Effects of EPA, DHA on the secretion of NO, expression of iNOS mRNA and DNA-binding activity of NFkappaB in human monocyte].
Chen, Y; Feng, X; Su, Y; Xia, Y, 2007
)
0.34
"Potential reasons for this non-significant result may be found in a dose-response relationship, advancement of disease progression in our sample population, or potentially the lack of a significant relationship between fish oil and tHcy."( Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients.
Beavers, DP; Beavers, KM; Bowden, RG; Gentile, M; Wilson, RL, 2008
)
0.35
"We examined the antidepressant efficacy and dose-response pattern of the n-3 docosahexaenoic acid (DHA)."( A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder.
Alpert, JE; Best-Popescu, C; Dording, CM; Fava, M; Laposata, M; Merens, W; Mischoulon, D; Murakami, JL; Nierenberg, AA; Papakostas, GI; Sonawalla, SB; Wu, SL, 2008
)
0.35
" There was no clear dose-response relationship between EPA+DHA intake and (sudden) coronary death."( Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zutphen study.
Boshuizen, HC; Kok, FJ; Kromhout, D; Ocké, MC; Streppel, MT, 2008
)
0.35
" The dose-response relation for DHA and EPA on reduction in deaths from cardiac causes was not significant."( Effect of fish oil on arrhythmias and mortality: systematic review.
Chatterley, T; Dorgan, M; León, H; Shibata, MC; Sivakumaran, S; Tsuyuki, RT, 2008
)
0.35
"When dosed appropriately, fish oil-based lipid emulsions contain sufficient EFAs to prevent EFAD."( The essentiality of arachidonic acid and docosahexaenoic acid.
de Meijer, VE; Gura, KM; Le, HD; Meisel, JA; Puder, M,
)
0.13
" Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA omega-3 PUFA that provides maximal cardioprotection in those at risk of CV disease as well in the treatment of atherosclerotic, arrhythmic, and primary myocardial disorders."( Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie, CJ; Mehra, MR; Milani, RV; Ventura, HO, 2009
)
0.35
" Body mass index and baseline fatty acid concentrations modulated the dose-response effects of omega-3 PUFA supplements on serum EPA and DHA and breast adipose tissue DHA."( Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition.
Belury, MA; Clinton, SK; Cole, RM; Hsu, JC; Lehman, A; Lester, JL; Li, Y; Richardson, JR; Yee, LD, 2010
)
0.36
"We assessed the dose-response relations within a low range of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and fish intake on fatal coronary heart disease (CHD) and nonfatal myocardial infarction (MI)."( Marine (n-3) fatty acids, fish consumption, and the 10-year risk of fatal and nonfatal coronary heart disease in a large population of Dutch adults with low fish intake.
Boer, JM; de Goede, J; Geleijnse, JM; Kromhout, D; Verschuren, WM, 2010
)
0.6
" Across these 15 studies, the dose-response was modeled using a first-order elimination curve."( Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides.
Binns, MA; Elliot, JA; Kocenas, AC; Lemke, S; Lloyd, H; Musa-Veloso, K; Oppedal-Olsen, H; Poon, T; Rice, H, 2010
)
0.65
" Although flax oil may decrease severity of illness in children and adolescents with bipolar disorder who have meaningful increases in serum EPA percent levels and/or decreased AA and DPA n-6 levels, individual variations in conversion of alpha-LNA to EPA and docosahexaenoic acid as well as dosing burden favor the use of fish oil both for clinical trials and clinical practice."( Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder.
Chirieac, MC; Costescu, S; Finucane, TL; Gracious, BL; Hibbeln, JR; Youngstrom, EA, 2010
)
0.36
" During the dosing period EPA increased 460-480% from the baseline concentration, while DHA increased 150-160%."( Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.
Kostner, K; Salm, P; Taylor, PJ, 2011
)
0.64
"Future RCTs to investigate the role of PUFA supplementation and risk for maternal perinatal depression should begin supplementation early in pregnancy and use a dosage closer to 2 g of DHA + EPA."( Maternal omega-3 fatty acid supplementation and risk for perinatal maternal depression.
Heyman, MB; Wojcicki, JM, 2011
)
0.37
"There was an inverse association, showing a dose-response relationship, between total n-3 fatty acid serum concentrations and p53 immunoreactivity in the whole epidermis and the basal layer."( Serum omega-3 and omega-6 fatty acids and cutaneous p53 expression in an Australian population.
Boyle, GM; Carr, SJ; Green, AC; Hughes, MC; Parsons, PG; van der Pols, JC; Xu, C, 2011
)
0.37
" Several intervention trials (n=8) have been done but generally suffer from small sample size and vary in terms of the study subject characteristics and timing, duration and dosage of the intervention."( Fatty acid status and maternal mental health.
Ramakrishnan, U, 2011
)
0.37
"The cardioprotective actions of the fish oil (FO)-derived long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been demonstrated, and dose-response relationships have been defined."( The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes.
Calder, PC; Cordell, H; Lietz, G; Madden, J; Mathers, JC; Miles, EA; Minihane, AM; Williams, CM, 2011
)
0.58
" The Fat-1 mice had a shift to the right in the dose-response relationship for methacholine induced bronchoconstriction with a significant increase in the log ED200."( Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses.
Bilal, S; Haworth, O; Kang, JX; Levy, BD; Weylandt, KH; Wu, L, 2011
)
0.37
" We will also gather information on secondary outcome measures which will include: omega-3 fatty acid concentrations in maternal plasma and cord blood, pro-inflammatory cytokine levels (IL-1β, IL-6, and TNF-α) in maternal and cord blood, need for and dosage of antidepressant medications, and obstetrical outcomes."( The mothers, Omega-3 and mental health study.
Allbaugh, L; Berman, D; Chilimigras, J; Djuric, Z; Hamilton, S; Keeton, K; Klemens, C; Marcus, S; Mozurkewich, E; Vahratian, A; Vazquez, D, 2011
)
0.37
" Secondary analyses were conducted to determine the effects of dosing of different omega-3 fatty acids in supplements."( Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis.
Bloch, MH; Qawasmi, A, 2011
)
0.37
" Participants in the intervention arm received capsules containing fish-oil at a daily dosage of 1720 mg of docosahexaenoic acid and 600 mg of eicosapentaenoic acid while the placebo arm received the equivalent amount of olive oil in their capsules."( The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older ad
Burns, NR; Danthiir, V; Nettelbeck, T; Wilson, C; Wittert, G, 2011
)
0.57
" Furthermore, no significant preventive effect was observed in subgroup analyses by the following: country location, inland or coastal geographic area, history of CVD, concomitant medication use, type of placebo material in the trial, methodological quality of the trial, duration of treatment, dosage of eicosapentaenoic acid or docosahexaenoic acid, or use of fish oil supplementation only as treatment."( Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Kwak, SM; Lee, YJ; Myung, SK; Seo, HG, 2012
)
0.81
" In women, an inverse dose-response relation (P-trend = 0."( Gender-specific associations of marine n-3 fatty acids and fish consumption with 10-year incidence of stroke.
Boer, JM; de Goede, J; Geleijnse, JM; Kromhout, D; Verschuren, WM, 2012
)
0.38
" This study evaluated the effect of n-3 PUFA in a low, but recommended cardioprotective dosage on the formation of 5-lipoxygenase pathway metabolites in overweight subjects."( The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: a randomized controlled trial.
Aardestrup, I; Gammelmark, A; Madsen, T; Nielsen, MS; Obel, T; Schmidt, EB, 2012
)
0.38
"Omega-3 fatty acids reduced heart rate (HR) and blood pressure (BP) in some studies, but dose-response studies are rare, and little is known about underlying mechanisms."( Effects of marine-derived omega-3 fatty acids on systemic hemodynamics at rest and during stress: a dose-response study.
Harris, WS; Kris-Etherton, PM; Skulas-Ray, AC; West, SG, 2012
)
0.38
" When choosing a product, it is important that label claims for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are met, especially when a specific dosage is required."( Quality analysis of commercial fish oil preparations.
Budge, SM; Jovica, F; Ritter, JC, 2013
)
0.63
"8%) subjects dosed with OM-3 FFA maintained an AUC(0-t) that was ≥50% of the respective high-fat AUC(0-t) in contrast to only 3 of 50 (6."( A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson, MH; Johnson, J; Kling, DF; Kyle, ML; Rooney, MW,
)
0.13
" However, the human data are inconclusive as to whether omega-3 PUFA supplementation at this dosage is effective in attenuating the inflammatory and immunomodulatory response to exercise and improving exercise performance."( Omega-3 polyunsaturated fatty acids in physical performance optimization.
Mickleborough, TD, 2013
)
0.39
" Focusing on clinical issues, this article reviews the impact of n-3FAs on these conditions and covers the relevant research, side effects, dosage guidelines, and drug interactions; clinicians should thus be able to better advise patients who are already taking n-3FAs or are interested in trying them."( Omega-3 fatty acids in psychiatry.
Freeman, MP; Mischoulon, D, 2013
)
0.39
"Red cell and plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid concentrations increased over the four weeks of dosing in the O3 group."( A randomized trial of fish oil omega-3 fatty acids on arterial health, inflammation, and metabolic syndrome in a young healthy population.
Collier, SR; McGinn, MC; Root, M; West, KL; Zwetsloot, KA, 2013
)
0.67
"To explore the rationale for ω-3 fatty acids in heart failure treatment, the dosage of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) for replacing low levels of highly unsaturated fatty acids (HUFA deficiency) was examined."( Replacement of reduced highly unsaturated fatty acids (HUFA deficiency) in dilative heart failure: dosage of EPA/DHA and variability of adverse peroxides and aldehydes in dietary supplement fish oils.
Alter, P; Rupp, H; Rupp, KG; Rupp, TP, 2013
)
0.61
" Supplementing DHA to the diet of PKU patients may improve their LCPUFA status; however, further research is needed to determine the optimal supplementation dosage and to establish beneficial functional outcomes."( Lower n-3 long-chain polyunsaturated fatty acid values in patients with phenylketonuria: a systematic review and meta-analysis.
Decsi, T; Fekete, K; Lohner, S, 2013
)
0.39
"After adjustment for age, sex, and other confounders, negative dose-response associations between the contents of individual n-3 polyunsaturated fatty acids in the erythrocyte membrane and the prevalence of carotid artery wall thickening and plaque were observed."( Erythrocyte membrane n-3 fatty acid levels and carotid atherosclerosis in Chinese men and women.
Chen, CG; Chen, YM; Dai, XW; Su, YX; Wang, P; Zhang, B, 2014
)
0.4
" A total of 66 RTT girls were evaluated, half of whom being treated for 12 months with a dietary supplementation of ω-3 PUFAs at high dosage (docosahexaenoic acid ~71."( Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome.
Cannarile, P; Ciccoli, L; De Felice, C; Durand, T; Favilli, R; Hayek, J; Leoncini, S; Lunghetti, S; Maffei, S; Montomoli, B; Pecorelli, A; Signorini, C, 2014
)
0.4
" The concentrations of IL-1β increased only with the highest dosage of sardine."( Influence of feeding graded levels of canned sardines on the inflammatory markers and tissue fatty acid composition of Wistar rats.
Alfaia, CM; Bandarra, NM; Batista, I; Bispo, P; Lopes, PA; Martins, SV; Miguéis, S; Pinto, RM; Prates, JA; Ramos, C; Rodrigues, PO; Rolo, EA, 2014
)
0.4
" Also, early phase studies with pharmaceuticals determine pharmacokinetics and pharmacodynamics to design the dose of the RCT intervention so that it is in a predicted linear dose-response range."( Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients.
Cleland, LG; James, MJ; Metcalf, RG; Sullivan, TR, 2014
)
0.4
" We evaluated the dose-response effect of EPA+DHA supplementation on circulating TNF-α, IL-6, and CRP and explored associations between red blood cell (RBC) membrane PUFA content and TNF-α, IL-6, and CRP."( Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults.
Fleming, JA; Flock, MR; Gaugler, TL; Harris, WS; Kris-Etherton, PM; Skulas-Ray, AC, 2014
)
0.4
" The aim of this study was to investigate the dose-response relation between low doses (<2 g/d) of EPA+DHA from FO, incorporated in a low-fat PS-enriched spread, and TG concentrations."( Low doses of eicosapentaenoic acid and docosahexaenoic acid from fish oil dose-dependently decrease serum triglyceride concentrations in the presence of plant sterols in hypercholesterolemic men and women.
Demonty, I; Olsson, J; Quadt, JF; Ras, RT; Trautwein, EA; Zebregs, YE, 2014
)
0.77
" We therefore examined dose-response relationships between fatty acids and PPARα transactivation in HepG2 cells."( Fatty acid chain length and saturation influences PPARα transcriptional activation and repression in HepG2 cells.
Konings, M; Mensink, RP; Plat, J; Popeijus, HE; Serbonij, K; van der Krieken, SE; van Otterdijk, SD, 2014
)
0.4
" Nonetheless, evidence from randomized clinical trials is comparatively sparse and leaves unclear: (a) whether such effects are clinically significant, (b) whether effects of eicosapentaenoic acid and DHA differ, (c) which dimensions of cognitive function are affected, (d) the dose-response relationships, or (e) the time course of the response."( Long-chain omega-3 fatty acids and optimization of cognitive performance.
Conklin, SM; Manuck, SB; Muldoon, MF; Ryan, CM; Yao, JK, 2014
)
0.6
" Hydroxyurea treated group was on dosage more than 20 mg/kg/day."( Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.
Daak, AA; Elbashir, LM; Elbashir, MI; Elderdery, AY; Ghebremeskel, K; Mariniello, K; Mills, J; Scarlett, G, 2015
)
0.42
" Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2."( Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia.
Alaupovic, P; Kris-Etherton, PM; Skulas-Ray, AC; West, SG,
)
0.35
" We also characterized the dose-response effects of n-3 fatty acid supplementation on RBC n-3 DPA after five months of supplementation with fish oil (Study 1: 0, 300, 600, 900, and 1800 mg/day EPA + DHA) and eight weeks of prescription n-3 ethyl esters (Study 2: 0, 850, and 3400 mg/day EPA + DHA)."( Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation.
Flock, MR; Harris, WS; Kris-Etherton, PM; Richter, CK; Skulas-Ray, AC; West, SG, 2015
)
0.42
" Electroretinography studies did not reveal any retinal damage after multiple dosing of RX-10045 micellar solution."( Topical delivery of aqueous micellar resolvin E1 analog (RX-10045).
Cholkar, K; Gilger, BC; Mitra, AK, 2016
)
0.43
"The percentages of EPA, DHA, and the omega-6 arachidonic acid (AA) were measured in RBCs at baseline and posttreatment in 122 participants with DSM-IV major depression who were randomly assigned between May 2005 and December 2008 to receive either 50 mg/d of sertraline and a daily dosage of 930 mg EPA/750 mg DHA or sertraline plus placebo."( Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements.
Carney, RM; Freedland, KE; Harris, WS; Rich, MW; Rubin, EH; Steinmeyer, BC, 2016
)
0.43
" Omega-3 supplementation may be an effective treatment for depression, but the requisite dosage and duration of treatment may depend on the patient's baseline level of omega-3 fatty acids."( Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements.
Carney, RM; Freedland, KE; Harris, WS; Rich, MW; Rubin, EH; Steinmeyer, BC, 2016
)
0.43
" Dose-response was evaluated in stratified dose or intake analyses."( A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk.
Alexander, DD; Bylsma, LC; Kuratko, CN; Miller, PE; Van Elswyk, ME, 2017
)
0.46
"Baseline-adjusted steady-state EPA exposure was similar after dosing with OM3-CA 4 g/day versus IPE 4 g/day (LSM ratio, area under the concentration-time curve from time 0 to 24 h: 93."( Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
Abu-Rashid, M; Chai, P; Davidson, M; Nilsson, C; Offman, E, 2017
)
0.46
" Thus, n-3 ingestion may beneficially interfere in PD progression, depending on the duration and dosage of consumption."( n-3 Ingestion may modulate the severity of periodontal disease? Systematic review.
Azzi, DV; Marques, LS; Pereira, LJ; Ribeiro Lima, R; Viafara, JAS; Zangeronimo, MG, 2018
)
0.48
"The addition of ALA/n-3 PUFAs to amitriptyline treatment in patients with VBD/PBS appears to improve outcomes and may allow for a lower dosage of amitriptyline, which may lead to fewer adverse effects."( Alpha Lipoic Acid Plus Omega-3 Fatty Acids for Vestibulodynia Associated With Painful Bladder Syndrome.
Felice, R; Gambini, D; Graziottin, A; Murina, F, 2017
)
0.46
" A dose-response effect was observed across the BMI spectrum."( Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial.
Arnold, LE; Belury, MA; Christian, LM; Fristad, MA; Gracious, BL; Mitchell, AM; Young, AS, 2017
)
0.46
" Personalized dosing of DHA in those who take aspirin may be a beneficial option for patients with type 2 diabetes mellitus."( Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus.
Abdolahi, A; Block, RC; Holub, A; Mousa, SA; Oda, MN; Tu, XM, 2017
)
0.46
" Future research will include better identification of the determinants of variation of responses to increased intake of EPA and DHA; more in-depth dose-response studies of the effects of EPA and DHA; clearer identification of the specific roles of EPA, docosapentaenoic acid and DHA; testing strategies to enhance delivery of n-3 fatty acids to the bloodstream; and exploration of sustainable alternatives to fish-derived very long-chain n-3 fatty acids."( Very long-chain n-3 fatty acids and human health: fact, fiction and the future.
Calder, PC, 2018
)
0.48
" Over a half of tested products provides the supplementary dose (250 mg/day) with one capsule taken daily, and in 27% of cases the daily dosage should be doubled."( ANALYSIS OF ω-3 FATTY ACID CONTENT OF POLISH FISH OIL DRUG AND DIETARY SUPPLEMENTS.
Jaworska, J; Osadnik, K, 2016
)
0.43
" However, to be utilised as biomarkers, to predict dietary intake, dose-response curves that cover a spectrum of intakes are required."( Effect of supplementation with flaxseed oil and different doses of fish oil for 2 weeks on plasma phosphatidylcholine fatty acids in young women.
Crowe, FL; Hodson, L; McLachlan, KJ; Skeaff, CM, 2018
)
0.48
" We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression."( Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid, AS; AlAbdulghafoor, FK; Biswas, P; Brainard, JS; Brown, TJ; Deane, KH; Hooper, L; Moore, HJ; Song, F; Summerbell, CD; Thorpe, GC; Worthington, HV, 2018
)
0.48
" Blood samples were collected for 24 h after dosing to analyze DHA and EPA plasma concentrations using a validated methodology."( A randomized trial comparing omega-3 fatty acid plasma levels after ingestion of emulsified and non-emulsified cod liver oil formulations.
Burgher-Kennedy, N; Conus, N; Kaur Datta, G; van den Berg, F, 2019
)
0.51
" Compared with the EE form, repeated daily dosing of the SMEDS formulations for 12 wk resulted in higher concentrations of EPA and DHA in plasma (P = 0."( A Novel Self-Micro-Emulsifying Delivery System Enhances Enrichment of Eicosapentaenoic Acid and Docosahexaenoic Acid after Single and Repeated Dosing in Healthy Adults in a Randomized Trial.
Calder, PC; Hustvedt, SO; Kindberg, GM; West, AL, 2018
)
0.71
"Compared with standard EEs, a SMEDS results in greater incorporation of EPA and DHA into blood pools after a single dose and with repeated daily dosing in healthy adults."( A Novel Self-Micro-Emulsifying Delivery System Enhances Enrichment of Eicosapentaenoic Acid and Docosahexaenoic Acid after Single and Repeated Dosing in Healthy Adults in a Randomized Trial.
Calder, PC; Hustvedt, SO; Kindberg, GM; West, AL, 2018
)
0.71
" We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression."( Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid, AS; AlAbdulghafoor, FK; Biswas, P; Brainard, JS; Brown, TJ; Deane, KH; Hooper, L; Moore, HJ; Song, F; Summerbell, CD; Thorpe, GC; Worthington, HV, 2018
)
0.48
" These findings suggest that supplemental fish oil requires continuous education and dosing guidance."( Comparing patients' prescribed, self-reported, and actual intake of supplemental eicosapentaenoic acid + docosahexaenoic acid.
Backes, JM; Burkhardt, CD; Melton, BL; Moriarty, PM; Ruisinger, JF,
)
0.36
"Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)."( New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason, R, 2019
)
0.51
" Novel therapeutic platforms such as RNA inhibition present opportunities to combine robust lipid lowering with infrequent dosing regimens, introducing therapies with vaccine-like properties."( Moving Targets: Recent Advances in Lipid-Lowering Therapies
Holleboom, AG; Kastelein, JJP; Larsen, LE; Stoekenbroek, RM, 2019
)
0.51
" There is no information on the dose-response of oxylipin concentrations after n-3 PUFA intake."( Plasma oxylipins respond in a linear dose-response manner with increased intake of EPA and DHA: results from a randomized controlled trial in healthy humans.
Browning, LM; Calder, PC; Jebb, SA; Ostermann, AI; Schebb, NH; Schoenfeld, K; Walker, CG; West, AL, 2019
)
0.51
" Additionally, we remark how duration periods, different cognitive baseline status in subjects, dosage of n-3 LCPUFAs administration and the presence of other factors might be related to different outcomes."( Omega-3 fatty acids and cognitive decline: a systematic review.
Fortique, F; Martí Del Moral, A, 2019
)
0.51
"Knowledge of the diurnal variation in circulating omega-3 polyunsaturated fatty acids (n-3 PUFAs) may be an important consideration for the development of dosing protocols designed to optimise tissue delivery of these fatty acids."( Diurnal rhythm of plasma EPA and DHA in healthy adults.
Avery, H; Calder, PC; Forster, J; Husberg, C; Hustvedt, SO; Jackson, PA; Kennedy, DO; Khan, J, 2020
)
0.56
" We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression."( Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Abdelhamid, AS; Biswas, P; Brainard, JS; Brown, TJ; Deane, KH; Hooper, L; Moore, HJ; Song, F; Summerbell, CD; Thorpe, GC; Worthington, HV, 2020
)
0.56
" The study period consisted of 8-wk dosing and 4-wk posttreatment observation."( l-Serine and EPA Relieve Chronic Low-Back and Knee Pain in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
Hashimoto, M; Kobuna, Y; Mine, T; Nagao, K; Nishikata, N; Sasahara, I; Suga, Y; Suzuki, K; Takada, M; Takeshita, M; Yamamoto, A, 2020
)
0.56
" The strength of the association depended on the dosage of eicosapentaenoic acid."( Omega-3 Polyunsaturated Fatty Acid Supplementation in Patients with Lower Extremity Arterial Disease.
Cheng, YC; Huang, YC; Liu, CW; Su, MI,
)
0.37
" The results indicated a dose-response relationship, as correlation analysis recovered a significant positive correlation between weight change and compliance to the fish oil enriched nutritional supplement at both week 2 and 5 (p < 0."( N-3 fatty acid EPA supplementation in cancer patients receiving abdominal radiotherapy - A randomised controlled trial.
Andersen, JR; Muhic, A; Møller, G; Patursson, P, 2021
)
0.62
" Post hoc analysis of dose-response relations indicate a positive correlation between the compliance and the ability to reduce weight loss in cancer patients during radiotherapy treatment."( N-3 fatty acid EPA supplementation in cancer patients receiving abdominal radiotherapy - A randomised controlled trial.
Andersen, JR; Muhic, A; Møller, G; Patursson, P, 2021
)
0.62
" To increase adherence to ASA and n3 PUFA supplementation, combination dosage form may be required to improve outcomes."( Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas.
Block, RC; Mousa, SA; Wang, IE; Yi, S, 2022
)
0.72
"Data were collected on study characteristics and methods; number of cases/deaths (for observational studies); categories of exposure; model covariates; risk estimates from the most-adjusted model; type and dosage of supplementation (from RCTs); fatty acid levels in blood; and differences in cognition test results before and after supplementation."( Fish intake, n-3 fatty acid body status, and risk of cognitive decline: a systematic review and a dose-response meta-analysis of observational and experimental studies.
Kasdagli, MI; Kosti, RI; Kyrozis, A; Lagiou, P; Naska, A; Orsini, N; Taiganidou, F, 2022
)
0.72
"These results show that the full biological impact of PUFA supplementation is far wider than any single-organ effect and implies that supplementation and dosing with PUFAs require a system-level assessment."( Dietary PUFAs drive diverse system-level changes in lipid metabolism.
Chiarugi, D; Furse, S; Koulman, A; Snowden, SG; Stevenson, PC; Vidal-Puig, A; Virtue, S, 2022
)
0.72
"Background Current evidence might support the use of omega-3 fatty acids (preferably docosahexaenoic acid and eicosapentaenoic acid) for lowering blood pressure (BP), but the strength and shape of the dose-response relationship remains unclear."( Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials.
Chen, BE; Li, X; Ritonja, JA; Zhang, X; Zhou, N, 2022
)
0.93
"0 g/day (2×1 g twice daily) with dosing after standard meals for 28 days."( Pharmacokinetics of Icosapent Ethyl: An Open-Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects.
Chen, H; Chen, W; Li, H; Li, J; Li, X; Li, Y; Liu, C; Sheng, L; Xu, H; Yang, M; Yuan, F, 2023
)
0.91
" In addition, a dose-response relationship was observed between an increasing level of EPA, DPA, or DHA biomarker and lower risk of CVD."( Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality.
Chen, F; Jia, W; Jiang, H; Li, C; Lin, J; Liu, X; Liu, Y; Lv, J; Ma, L; Mi, B; Wang, D; Wang, F; Wang, L; Wu, M; Yan, N, 2022
)
0.72
" The aim of this study was to assess whether a personalized dosage of omega-3 supplementation would lead to an O3I ≥ 8%."( Optimization of Omega-3 Index Levels in Athletes at the US Naval Academy: Personalized Omega-3 Fatty Acid Dosage and Molecular Genetic Approaches.
Deuster, P; Rittenhouse, M; Sambuughin, N, 2022
)
0.72
" However, it was not possible to conclude whether the two FADS1/2 variants led to differential increases in OI3 or if a personalized dosage of omega-3 supplementation led to an O3I ≥ 8%, due to our study limitations."( Optimization of Omega-3 Index Levels in Athletes at the US Naval Academy: Personalized Omega-3 Fatty Acid Dosage and Molecular Genetic Approaches.
Deuster, P; Rittenhouse, M; Sambuughin, N, 2022
)
0.72
" However, fundamental knowledge of n-3 polyunsaturated fatty acid dosing in athletes such as ASF players remains poorly understood."( The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes.
Burns, JL; Choi, SH; Gable, DA; Jones, MT; Krk, M; Lust, CAC; Ma, DWL; Oliver, JM; Smith, SB, 2023
)
0.91
" A repeated-measures ANOVA was conducted to assess the dose-response effect of DHA over time, and between-group differences at individual time points were assessed by one-way ANOVA followed by Tukey post hoc test."( The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes.
Burns, JL; Choi, SH; Gable, DA; Jones, MT; Krk, M; Lust, CAC; Ma, DWL; Oliver, JM; Smith, SB, 2023
)
0.91
"Our findings provide important fundamental knowledge demonstrating a dose-response incorporation of DHA into RBC membranes up to 6 g·d -1 ."( The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes.
Burns, JL; Choi, SH; Gable, DA; Jones, MT; Krk, M; Lust, CAC; Ma, DWL; Oliver, JM; Smith, SB, 2023
)
0.91
"4 g and above for as little as 1 month-6 months were identified as the most effective dosage ranges for increasing blood levels of omega-3s to therapeutic levels in people with atherosclerotic disease."( The effect of omega-3 polyunsaturated fatty acid intake on blood levels of omega-3s in people with chronic atherosclerotic disease: a systematic review.
Delaney, CL; Miller, MD; Nayda, NC; Thomas, JM, 2023
)
0.91
" These findings support the potential neurotherapeutic effects of high dosage EPA-dominant omega-3 PUFAs for the amelioration of cognitive decline in patients with AD."( Efficacy and acceptability of anti-inflammatory eicosapentaenoic acid for cognitive function in Alzheimer's dementia: A network meta-analysis of randomized, placebo-controlled trials with omega-3 fatty acids and FDA-approved pharmacotherapy.
Carvalho, AF; Chen, TY; Chen, YW; Cheng, YS; Correll, CU; Hsu, CW; Kuo, JS; Li, DJ; Liang, CS; Lin, PY; Shiue, YL; Stubbs, B; Su, KP; Suen, MW; Sun, CK; Tseng, PT; Tu, YK; Wu, MK; Wu, YC; Yeh, PY; Zeng, BS; Zeng, BY, 2023
)
1.17
"Background Previous results provide supportive but not conclusive evidence for the use of omega-3 fatty acids to reduce blood lipids and prevent events of atherosclerotic cardiovascular disease, but the strength and shape of dose-response relationships remain elusive."( Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials.
Chen, BE; Li, B; Li, X; Shen, Y; Wang, T; Zhang, X; Zhou, N, 2023
)
0.91
" We used multivariable Cox regression to estimate the HRs of AF across quintiles of ω-3 fatty acid consumption and a cubic spline analysis to assess the dose-response relations between ω-3 fatty acids and AF."( Dietary ω-3 fatty acids and the incidence of atrial fibrillation in the Million Veteran Program.
Benjamin, EJ; Cho, K; Djoussé, L; Gaziano, JM; Guardino, ET; Li, Y; Nguyen, XM; Wilson, PWF, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (130 Product(s))

Product Categories

Product CategoryProducts
Pet Supplies15
Vitamins & Supplements96
Professional Supplements18
Active Lifestyle & Fitness1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Abound Pro Dry Puppy Food Vet Formulated Chicken Brown Rice -- 8 lbsAboundPet SuppliesVitamin C, Vitamin E, EPA, Vitamin E, Phosphorus, Vitamin A, Taurine2024-11-29 10:47:42
AC Grace Unique E -- 60 SoftgelsAC GraceVitamins & Supplements astaxanthin, Vitamin D3, Coenzyme Q10, Vitamin E, EPA, Vitamin E, lycopene2024-11-29 10:47:42
Amazing Nutrition Amazing Omega - Krill Oil -- 1000 mg - 120 SoftgelsAmazing NutritionVitamins & SupplementsEPA2024-11-29 10:47:42
Amazing Nutrition Amazing Omega - Norwegian Fish Oil Orange -- 1250 mg - 120 SoftgelsAmazing NutritionVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Amazing Nutrition Amazing Omega - Triple Strength Fish Oil Lemon -- 1360 mg - 120 SoftgelsAmazing NutritionVitamins & SupplementsEPA2024-11-29 10:47:42
Amazing Nutrition Amazing Omega Wild Alaskan Salmon Oil -- 2000 mg - 180 SoftgelsAmazing NutritionVitamins & SupplementsEPA2024-11-29 10:47:42
AMEN Omega-3 EPA DHA Fatty Acids Fish Oil - Brain Health & Cognition -- 90 SoftgelsAMENVitamins & SupplementsEPA2024-11-29 10:47:42
Amy Myers MD Complete Omega-3 Softgels -- 60 SoftgelsAmy Myers MDProfessional SupplementsEPA2024-11-29 10:47:42
BioSchwartz Omega-3 Fish Oil -- 90 SoftgelsBioSchwartzVitamins & SupplementsEPA2024-11-29 10:47:42
Carlson Cod Liver Oil Gems Super -- 1000 mg - 250 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Cod Liver Oil Gems™ Super -- 1000 mg - 100 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Elite EPA Gems -- 1000 mg - 120 SoftgelsCarlsonVitamins & SupplementsEPA2024-11-29 10:47:42
Carlson Elite Omega-3 Gems Lemon -- 1600 mg - 240 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Elite Omega-3 Gems® Fish Oil Wild Caught Lemon -- 1600 mg - 90 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Elite Omega-3 plus D & K Natural Lemon -- 90 SoftgelsCarlsonVitamins & SupplementsEPA, Vitamin K2, MK-7, Vitamin K22024-11-29 10:47:42
Carlson Fish Oil BOGO Lemon -- 120 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Maximum Omega 2000 Natural Lemon -- 120 SoftgelsCarlsonVitamins & SupplementsEPA2024-11-29 10:47:42
Carlson Maximum Omega 2000™ Natural Lemon -- 180 SoftgelsCarlsonVitamins & SupplementsEPA2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Lemon -- 460 mg - 150 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Lemon -- 8.4 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Unflavored -- 16.9 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Dietary Supplement Unflavored -- 8.4 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Norwegian Cod Liver Oil Gems Natural Lemon -- 460 mg - 300 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Norwegian MedOmega™ Fish Oil Concentrate Lemon Lime -- 3.3 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Norwegian Salmon Oil BOGO 180 Ct + 50 Ct -- 500 mg - 180 Softgels Each / Pack of 2CarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Norwegian The Very Finest Fish Oil Natural Orange -- 16.9 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Solar D Gems Natural Lemon -- 4000 IU - 120 SolidCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Super D Omega-3 Lemon -- 8.4 fl ozCarlsonVitamins & SupplementsVitamin D3, Vitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Carlson Super DHA Gems® -- 500 mg - 180 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Super Omega-3 Gems® -- 250 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Super Omega-3 Gems® 30 FREE Soft Gels -- 100 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson The Very Finest Fish Oil Lemon -- 1600 mg - 6.7 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson The Very Finest Fish Oil Orange -- 240 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson The Very Finest Fish Oil- Omega-3s Natural Orange -- 700 mg - 150 SoftgelsCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Carlson Wild Norwegian Cod Liver Oil Natural Lemon -- 1100 mg - 16.9 fl ozCarlsonVitamins & SupplementsVitamin E, EPA, Vitamin E, Vitamin A2024-11-29 10:47:42
Chew + Heal Allergy Aid Immune Boost Supplement for Dogs -- 90 Soft ChewsChew + HealPet SuppliesEPA, Quercetin2024-11-29 10:47:42
Chew + Heal Omega Skin + Coat Supplement for Dogs Peanut Butter -- 180 Soft ChewsChew + HealPet Suppliesalpha-Linolenic Acid, EPA, Linoleic Acid2024-11-29 10:47:42
Chew + Heal Pure Cod Liver Oil Omega Single Ingredient for Dogs -- 16 fl ozChew + HealPet SuppliesEPA2024-11-29 10:47:42
Chew + Heal Pure Wild Alaskan Salmon Oil Single Ingredient for Dogs -- 16 fl ozChew + HealPet SuppliesEPA2024-11-29 10:47:42
Chew + Heal Pure Wild Alaskan Salmon Oil Single Ingredient for Dogs -- 32 fl ozChew + HealPet SuppliesEPA2024-11-29 10:47:42
Childlife Cod Liver Oil Natural Strawberry -- 8 fl ozChildlifeVitamins & SupplementsEPA2024-11-29 10:47:42
Childlife Omega-3 DHA + Choline SoftMelts Natural Passion Fruit -- 27 GummiesChildlifeVitamins & SupplementsVitamin D3, Choline, EPA2024-11-29 10:47:42
Childlife PreNatal DHA Lemon -- 30 SoftgelsChildlifeVitamins & SupplementsEPA2024-11-29 10:47:42
Childlife Pure DHA Chewable Berry -- 90 SoftgelsChildlifeVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Coromega Omega-3 Max Citrus Burst -- 2400 mg - 60 PacketsCoromegaVitamins & SupplementsVitamin D3, EPA2024-11-29 10:47:42
Coromega Kids Omega 3 +Vitamin D Tropical Orange -- 30 PacketsCoromegaVitamins & SupplementsVitamin C, Vitamin D3, Vitamin E, EPA, Vitamin E2024-11-29 10:47:42
Coromega MAX High Concentrate Omega-3 Fish Oil Coconut Bliss -- 2400 mg - 60 Squeeze Shot PacketsCoromegaVitamins & SupplementsVitamin C, Vitamin D3, EPA2024-11-29 10:47:42
Coromega Omega 3 Plus D Squeeze Tropical -- 90 PacketsCoromegaVitamins & SupplementsEPA2024-11-29 10:47:42
Coromega Omega-3 Squeeze Orange -- 90 PacketsCoromegaVitamins & SupplementsVitamin C, Vitamin E, EPA, Vitamin E2024-11-29 10:47:42
Coromega Omega-3 Tropical Squeeze plus D Tropical Orange -- 120 PacketsCoromegaVitamins & SupplementsVitamin D3, EPA2024-11-29 10:47:42
Designs for Sport Omega 3 Hi-Po - NSF Certified for Sport -- 60 SoftgelsDesigns for SportProfessional SupplementsEPA2024-11-29 10:47:42
Deva Omega-3 DHA-EPA Liquid Lemon -- 2 fl ozDevaVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Deva Vegan Omega-3 DHA-EPA -- 300 mg - 90 SoftgelsDevaVitamins & SupplementsEPA2024-11-29 10:47:42
Dr. Mercola Wild Alaskan Cod Liver Oil -- 60 CapsulesDr. MercolaProfessional SupplementsEPA, Vitamin A2024-11-29 10:47:42
Enzymedica Aqua Biome Fish Oil Omega-3 Maximum Strength Hint Of Lemon -- 60 SoftgelsEnzymedicaVitamins & SupplementsEPA2024-11-29 10:47:42
Futurebiotics Omega-3 Fish Oil -- 100 SoftgelsFuturebioticsVitamins & SupplementsEPA2024-11-29 10:47:42
Garden of Life Olde World® Icelandic Cod Liver Oil Lemon Mint -- 8 fl ozGarden of LifeVitamins & SupplementsEPA, Vitamin A2024-11-29 10:47:42
Healthy Pup Healthy Skin Omega Supplement for Dogs -- 180 Soft ChewsHealthy PupPet Suppliesalpha-Linolenic Acid, EPA, glycerin, Linoleic Acid, maltodextrin, sorbic acid2024-11-29 10:47:42
Igennus Pharmepa Restore - Ultra Pure EPA-Super Strength rTG Wild Fish Oil Lemon -- 1000 mg - 60 SoftgelsIgennusVitamins & SupplementsVitamin E, EPA, vitamin E2024-11-29 10:47:42
Integrative Therapeutics Pure Omega Liquid -- 6.8 fl ozIntegrative TherapeuticsProfessional SupplementsEPA2024-11-29 10:47:42
Irwin Naturals Double Potency Fish Oil Pure Natural Citrus -- 60 Liquid SoftgelsIrwin NaturalsVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
IWI Heart Support -- 60 SoftgelsIWIVitamins & SupplementsChlorophyll, EPA, glycerin, sorbitol2024-11-29 10:47:42
IWI Joint Omega-3 + Glucosamine and White Willow Bark -- 60 SoftgelIWIVitamins & SupplementsChlorophyll, Curcuminoids, EPA, glycerin, Salicin, sorbitol2024-11-29 10:47:42
IWI Made from Algae Brain Omega-3 -- 60 SoftgelsIWIVitamins & SupplementsChlorophyll, EPA, glycerin, Vitamin B6, Vitamin B62024-11-29 10:47:42
IWI Omega-3 EPA + DHA -- 60 Mini SoftgelsIWIVitamins & SupplementsChlorophyll, EPA, glycerin, sorbitol2024-11-29 10:47:42
IWI Omega-3 Essential -- 30 Vegan SoftgelsIWIVitamins & SupplementsChlorophyll, EPA, glycerin, sorbitol2024-11-29 10:47:42
Jarrow Formulas EPA-DHA Balance -- 240 SoftgelsJarrow FormulasVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
Jarrow Formulas Krill Oil -- 120 SoftgelsJarrow FormulasVitamins & SupplementsAstaxanthin, EPA, glycerin, tocopherols2024-11-29 10:47:42
Kaged Omega-3 Premium Triglyceride Fish Oil -- 60 SoftgelsKagedActive Lifestyle & FitnessEPA, glycerin2024-11-29 10:47:42
Klean Athlete Klean Omega - NSF Certified for Sport -- 60 SoftgelsKlean AthleteProfessional SupplementsEPA2024-11-29 10:47:42
Kyolic Aged Garlic Extract™ Omega 3 Cholesterol & Circulation -- 180 SoftgelsKyolicVitamins & SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Life Extension Super Omega-3 EPA-DHA with Sesame Lignans & Olive Extract -- 120 Enteric Coated SoftgelsLife ExtensionVitamins & SupplementsEPA, glycerin, maltodextrin2024-11-29 10:47:42
Mason Natural Glucosamine & Fish Oil -- 90 SoftgelsMason NaturalVitamins & SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Momentous Omega-3 - NSF Certified for Sport - 30 Servings -- 60 SoftgelsMomentousProfessional Supplementsannatto, EPA, glycerine2024-11-29 10:47:42
Natrol Extreme Omega Lemon -- 2400 mg - 60 SoftgelsNatrolVitamins & SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Natrol Omega 3-6-9 Complex Lemon -- 1200 mg - 60 SoftgelsNatrolVitamins & SupplementsAlpha-Linolenic Acid, EPA, glycerin, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Natrol Omega 3-6-9 Complex Heart Health Lemon -- 90 SoftgelsNatrolVitamins & SupplementsAlpha-Linolenic Acid, EPA, glycerin, Linoleic Acid, Oleic Acid2024-11-29 10:47:42
Natural Factors RxOmega-3 Factors -- 240 Enteripure SoftgelsNatural FactorsVitamins & SupplementsDocosapentaenoic Acid, EPA, glycerin2024-11-29 10:47:42
OceanBlue Everyday Omega Orange -- 30 SoftgelsOceanBlueVitamins & Supplementsd-limonene, EPA, glycerin2024-11-29 10:47:42
OceanBlue Everyday Omega Orange -- 90 SoftgelsOceanBlueVitamins & Supplementsd-limonene, EPA, glycerin2024-11-29 10:47:42
OceanBlue Everyday Omega Minis Orange -- 60 SoftgelsOceanBlueVitamins & Supplementsd-limonene, EPA, glycerin2024-11-29 10:47:42
OceanBlue Omega Mood Food -- 60 SoftgelsOceanBlueVitamins & Supplementsd-limonene, EPA, glycerin2024-11-29 10:47:42
OceanBlue Professional Omega 3 - 2100 with CoQ10 -- 90 SoftgelsOceanBlueProfessional SupplementsCoenzyme Q10, EPA, glycerin2024-11-29 10:47:42
OceanBlue Professional Omega 3 - 2100 with Turmeric -- 60 SoftgelsOceanBlueProfessional SupplementsD-limonene, EPA, titanium dioxide2024-11-29 10:47:42
OceanBlue Professional Omega 3 - 2100 with Vitamin K2 & D3 -- 60 SoftgelsOceanBlueProfessional SupplementsD-limonene, EPA, glycerin, vitamin K2, Vitamin K22024-11-29 10:47:42
OceanBlue Professional Omega-3 1300 Vegan Orange -- 60 Vegan SoftgelsOceanBlueProfessional Supplementsd-limonene, EPA, sorbitol2024-11-29 10:47:42
OceanBlue Professional Omega-3 2100 High Potency Natural Orange -- 120 SoftgelsOceanBlueProfessional SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
OceanBlue Professional Omega-3 2100 High Potency Natural Orange -- 60 SoftgelsOceanBlueProfessional SupplementsEPA, glycerin2024-11-29 10:47:42
OceanBlue Professional Omega-3 2100 with Vitamin D Natural Vanilla -- 120 SoftgelsOceanBlueProfessional SupplementsVitamin D3, Vitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
OceanBlue Professional Omega-3 2100 with Vitamin D Vanilla -- 60 SoftgelsOceanBlueVitamins & SupplementsVitamin D3, EPA, ethyl vanillin, glycerin2024-11-29 10:47:42
Ocuvite Adult 50+ Eye Vitamin & Mineral -- 90 Mini SoftgelsOcuviteVitamins & SupplementsVitamin C, carmine, Vitamin E, EPA, Vitamin E, glycerin, Lutein2024-11-29 10:47:42
Olly The Essential Prenatal Sweet Citrus -- 60 GummiesOllyVitamins & Supplementscitric acid, ascorbyl palmitate, Vitamin C, Choline, citric acid, Vitamin E, EPA, Folate, Vitamin E, lactic acid, Niacin, Vitamin B6, Vitamin A, sugar, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olly Ultra Strength Prenatal Folic Acid + DHA Multivitamin -- 60 SoftgelsOllyVitamins & SupplementsVitamin C, Biotin, Vitamin E, EPA, Folate, Vitamin E, glycerin, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Thiamin, titanium dioxide, Vitamin B12, Vitamin B62024-11-29 10:47:42
Olympian Labs Enteric Coated Omega-3 Fish Oil -- 2000 mg - 120 SoftgelsOlympian LabsVitamins & SupplementsVitamin E, EPA, triethyl citrate, Vitamin E, glyceryl monostearate, glycerin, propylene glycol, triacetin, vanillin2024-11-29 10:47:42
Olympian Labs Krill Oil -- 1000 mg - 60 SoftgelsOlympian LabsVitamins & SupplementsAstaxanthin, Omega-3, EPA, glycerin, Vitamin A, sorbitol2024-11-29 10:47:42
Olympian Labs Omega-3 Fish Oils -- 2000 mg - 120 SoftgelsOlympian LabsVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
Olympian Labs Omega-3 Fish Oils -- 2000 mg - 240 SoftgelsOlympian LabsVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Omax3 Ultra Pure Omega-3 -- 1500 mg - 60 SoftgelsOmax3Professional SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Omax3 Ultra Pure Pro-Strength Omega-3 - NSF Certified for Sport -- 3000 mg - 60 SoftgelsOmax3Professional SupplementsVitamin E, EPA, Vitamin E, glycerin2024-11-29 10:47:42
Paradise Herbs Med-Vita® Omega-Sure™ Omega-3 Fish Oil -- 1000 mg - 30 Vegetarian SoftgelsParadise HerbsVitamins & SupplementsEPA, sorbitol2024-11-29 10:47:42
Paradise Herbs Omega Sure® Omega-3 Concentrate -- 1000 mg - 60 Pesco Vegetarian SoftgelsParadise HerbsVitamins & SupplementsEPA, sorbitol2024-11-29 10:47:42
SmartyPants Adult Complete and Fiber -- 180 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, annatto, Vitamin C, Choline, citric acid, Vitamin E, EPA, Folate, Vitamin E, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Kids Formula Cherry Berry -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Choline, citric acid, Vitamin E, EPA, Folate, Vitamin E, Inositol, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Solgar Omega-3 Fish Oil Concentrate -- 240 SoftgelsSolgarVitamins & SupplementsEPA2024-11-29 10:47:42
Solgar Triple Strength Omega-3 EPA and DHA -- 950 mg - 100 SoftgelsSolgarVitamins & SupplementsEPA2024-11-29 10:47:42
Source Naturals Vegan Omega-3s EPA-DHA -- 300 mg - 60 Vegan SoftgelsSource NaturalsVitamins & Supplementsascorbyl palmitate, EPA, glycerin, sorbitol2024-11-29 10:47:42
Spectrum Essentials Fish Oil Omega-3 -- 1000 mg - 100 SoftgelsSpectrumVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
Spectrum Essentials Fish Oil Omega-3 -- 1000 mg - 250 SoftgelsSpectrumVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
Spectrum Fish Oil With Vitamin D -- 250 SoftgelsSpectrumVitamins & SupplementsVitamin D3, EPA2024-11-29 10:47:42
Sundown Naturals Odorless Omega-3 Fish Oil -- 1290 mg - 72 Coated Mini SoftgelsSundown NaturalsVitamins & SupplementsEPA, ethylcellulose2024-11-29 10:47:42
The Honest Kitchen Grain Free Dehydrated Dog Food Beef Recipe -- 2 lbsThe Honest KitchenPet Suppliesd- calcium pantothenate, choline chloride, EPA, vitamin B5, potassium chloride, potassium iodide, vitamin B2, taurine, vitamin B12024-11-29 10:47:42
The Honest Kitchen Grain Free Dehydrated Dog Food Turkey Recipe -- 10 lbsThe Honest KitchenPet Suppliescholine chloride, EPA, potassium chloride, potassium iodide, vitamin B12024-11-29 10:47:42
The Honest Kitchen Grain Free Dehydrated Dog Food Turkey Recipe -- 4 lbsThe Honest KitchenPet Suppliescalcium pantothenate, choline chloride, EPA, vitamin B5, potassium chloride, riboflavin, taurine, vitamin B12024-11-29 10:47:42
The Honest Kitchen Whole Grain Dehydrated Dog Food Chicken Recipe -- 10 lbsThe Honest KitchenPet Suppliescholine chloride, EPA, potassium chloride, potassium iodide, vitamin B12024-11-29 10:47:42
Thorne Research Super EPA -- 90 Gel CapsThorne ResearchProfessional Supplementsvitamin E, EPA, vitamin E2024-11-29 10:47:42
True Grace Omega-3 Fish Oil -- 120 SoftgelsTrue GraceVitamins & SupplementsEPA2024-11-29 10:47:42
True Grace Omega-3 Fish Oil -- 180 SoftgelsTrue GraceVitamins & SupplementsEPA2024-11-29 10:47:42
True Grace Omega-3 Fish Oil -- 60 SoftgelsTrue GraceVitamins & SupplementsEPA2024-11-29 10:47:42
True Grace Prenatal DHA -- 60 SoftgelsTrue GraceVitamins & SupplementsEPA2024-11-29 10:47:42
Twinlab Daily Omega Softgels -- 30 SoftgelsTwinlabVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
Vital Nutrients Ultra Pure Fish Oil 700 - General Health Maintenance Inflammatory Balance Joint & Cartilage -- 120 SoftgelsVital NutrientsProfessional SupplementsEPA, glycerin, tocopherols2024-11-29 10:47:42
Vital Nutrients Ultra Pure Fish Oil 800 -- 90 Softgel CapsulesVital NutrientsProfessional Supplementsascorbyl palmitate, EPA, glycerin2024-11-29 10:47:42
Zahler Omega 3 Platinum -- 2000 mg - 360 SoftgelsZahlerVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
Zenwise Omega-3 Gummies -- 30 GummiesZenwiseVitamins & SupplementsVitamin E, EPA, Vitamin E2024-11-29 10:47:42
Zenwise Vegan Omega-3 -- 475 mg - 120 SoftgelsZenwiseVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42
Zesty Paws Skin & Coat Fish Oil & Omega-3 Supplement for Dogs Chicken -- 90 Soft ChewsZesty PawsPet SuppliesAscorbic Acid, Biotin, Omega-3, Vitamin E, EPA, Vitamin E, sorbic acid2024-11-29 10:47:42
Zesty Paws Wild Alaskan Salmon Oil for Cats & Dogs Salmon -- 16 fl ozZesty PawsPet SuppliesEPA2024-11-29 10:47:42
Zesty Paws Wild Alaskan Salmon Oil for Cats & Dogs Salmon -- 32 ozZesty PawsPet SuppliesEPA2024-11-29 10:47:42
Zesty Paws Wild Alaskan Salmon Oil for Cats & Dogs -- 8 fl ozZesty PawsPet SuppliesEPA2024-11-29 10:47:42
Zhou Fish Oil - Purified Omega-3 -- 120 SoftgelsZhouVitamins & SupplementsEPA, glycerin2024-11-29 10:47:42

Roles (8)

RoleDescription
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
micronutrientAny nutrient required in small quantities by organisms throughout their life in order to orchestrate a range of physiological functions.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
Daphnia galeata metaboliteA Daphnia metabolite produced by the species Daphnia galeata.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
anticholesteremic drugA substance used to lower plasma cholesterol levels.
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
omega-3 fatty acidA family of polyunsaturated fatty acids that have in common a final carbon-carbon double bond in the omega-3 position, i.e., the third bond from the methyl end of the fatty acid.
icosapentaenoic acidAny straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (12)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Biosynthesis of specialized proresolving mediators (SPMs)13107
Biosynthesis of EPA-derived SPMs625
Biosynthesis of E-series 18(S)-resolvins518
Biosynthesis of electrophilic -3 PUFA oxo-derivatives227
Alpha Linolenic Acid and Linoleic Acid Metabolism517
Omega-3 / omega-6 fatty acid synthesis038
Mitochondrial beta-oxidation064
Elongation of (very) long chain fatty acids345
Folic acid network070
Selenium micronutrient network095

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency79.95990.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency79.43280.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency28.60660.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency26.83250.000221.22318,912.5098AID743035
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency8.43680.531815.435837.6858AID504845
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency10.68220.001019.414170.9645AID743094
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.01190.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency39.81070.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.49150.000323.4451159.6830AID743065
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency50.11870.010323.856763.0957AID2662
DNA polymerase kappa isoform 1Homo sapiens (human)Potency11.22020.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Protein (peroxisome Proliferator Activated Receptor (ppar-delta))Homo sapiens (human)IC50 (µMol)4.00004.00004.00004.0000AID977608
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)13.00000.00051.41288.2000AID360928
TrypsinSus scrofa (pig)IC50 (µMol)200.00000.50000.50000.5000AID402793
Cytochrome P450 1A2Homo sapiens (human)Ki7.63200.00561.15349.0000AID1615905
Coagulation factor VIIHomo sapiens (human)IC50 (µMol)78.00000.00020.83363.3000AID402795
AromataseHomo sapiens (human)IC50 (µMol)53.20000.00001.290410.0000AID376617
Tissue factorHomo sapiens (human)IC50 (µMol)78.00000.00010.734410.0000AID402795
Retinoic acid receptor RXR-alphaHomo sapiens (human)Ki7.63200.00040.56927.6320AID1615905
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)7.10000.00101.453910.0000AID360927
Oxoeicosanoid receptor 1Homo sapiens (human)IC50 (µMol)2.00000.00301.41722.0000AID1067780
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Kd2.00000.00120.95314.9800AID677050
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (150)

Processvia Protein(s)Taxonomy
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayOxoeicosanoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayOxoeicosanoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor activityOxoeicosanoid receptor 1Homo sapiens (human)
protein bindingOxoeicosanoid receptor 1Homo sapiens (human)
5-oxo-6E,8Z,11Z,14Z-icosatetraenoic acid bindingOxoeicosanoid receptor 1Homo sapiens (human)
5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic acid bindingOxoeicosanoid receptor 1Homo sapiens (human)
5(S)-hydroxyperoxy-6E,8Z,11Z,14Z-icosatetraenoic acid bindingOxoeicosanoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
plasma membraneOxoeicosanoid receptor 1Homo sapiens (human)
plasma membraneOxoeicosanoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID360927Inhibition of sheep COX2-mediated prostaglandin biosynthesis using [1-14C]arachidonic acid2001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID405533Inhibition of mPGES12008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID627878Inhibition of histidine-tagged human DNA polymerase gamma using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1289655Inhibition of SREBP2 maturation in human HepG2 cells at 50 uM after overnight incubation by immunoblot analysis2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID627877Inhibition of calf DNA polymerase alpha using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID701913Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2.
AID627876Inhibition of C-terminal His6-tagged human DNA polymerase kappa (amino acids 1 to 560) using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID396469Inhibition of tube formation in human EAhy926 cells at 50 uM after 24 hrs by phase-contrast microscopy2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
A new antiangiogenic C24 oxylipin from the soft coral Sinularia numerosa.
AID376617Inhibition of aromatase in human placental microsomes by radiometric method2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID1744328Displacement of 6-(Ethyl-{5-isobutoxy-4-isopropyl-2-[(10-oxo-2,3,5,6-tetrahydro-1H,4H,10H-11-oxa-3a-aza-benzo[de]anthracene-9-carbonyl)-amino]-phenyl}-amino)-nicotinic acid from human RXRalpha-LBD by by fluorescence binding assay
AID1067780Antagonist activity at human OXE receptor fused with G-alphai assessed as inhibition of 5-oxo-ETE-induced GTPgammaS binding after 60 mins by liquid scintillation counting analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Inhibition of 5-oxo-6,8,11,14-eicosatetraenoic acid-induced activation of neutrophils and eosinophils by novel indole OXE receptor antagonists.
AID1615905Displacement of CU-6PMN from human RXRalpha LBD incubated for 2 hrs by fluorescence based assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.
AID627879Inhibition of C-terminal His6-tagged human DNA polymerase kappa (amino acids 1 to 560) using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID402794Octanol-water partition coefficient, log P of the compound1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID627981Cytotoxicity against mouse RAW264.7 cells2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1289615Inhibition of SREBP2 in human HepG2 cells assessed as reduction of PCSK9 secretion at 50 uM after 16 hrs by ELISA2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.
AID701911Proapoptotic activity in human MDA-MB-468 cells assessed as activation of caspase-3 by luminometry2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2.
AID628060Inhibition of recombinant His-tagged human DNA polymerase lambda using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID627976Cytotoxicity against human HCT116 cells by WST-1 assay2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID376618Inhibition of aromatase in human SKBR3 cells at 100 uM relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID1616997Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 22019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID627880Inhibition of recombinant His-tagged human DNA polymerase lambda using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID627980Cytotoxicity against mouse RAW264.7 cells at 5 uM2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID360929Selectivity ratio for IC50 for sheep COX2 to IC50 for bovine COX22001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID627875Inhibition of histidine-tagged human DNA polymerase gamma using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID376615Inhibition of aromatase in human placental microsomes at 20 ug/ml by radiometric method relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID402793Inhibition of pig pancreatic trypsin after 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID627982Antiinflammatory activity in mouse assessed as inhibition of TPA-induced mouse ear edema at 500 ug/ear administered 30 mins before TPA challenge measured after 7 hrs relative to untreated control2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID402795Inhibition of amidolytic activity of human tissue factor/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID627874Inhibition of calf DNA polymerase alpha using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID323922Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 72 hrs by luciferase reporter assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID627979Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha secretion at 5 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID677050Binding affinity to PPARgamma2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.
AID360928Inhibition of bovine COX1-mediated prostaglandin biosynthesis using [1-14C]arachidonic acid2001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1999Molecular cell, Mar, Volume: 3, Issue:3
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors.
AID1811Experimentally measured binding affinity data derived from PDB1999Molecular cell, Mar, Volume: 3, Issue:3
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,863)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990590 (8.60)18.7374
1990's1011 (14.73)18.2507
2000's1416 (20.63)29.6817
2010's2805 (40.87)24.3611
2020's1041 (15.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 113.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index113.09 (24.57)
Research Supply Index9.04 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index219.51 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (113.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,304 (18.18%)5.53%
Reviews831 (11.59%)6.00%
Case Studies44 (0.61%)4.05%
Observational35 (0.49%)0.25%
Other4,957 (69.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]